CN112300099A - Ketal derivatives of drugs, preparation method thereof, pharmaceutical compositions and uses - Google Patents
Ketal derivatives of drugs, preparation method thereof, pharmaceutical compositions and uses Download PDFInfo
- Publication number
- CN112300099A CN112300099A CN202010175551.7A CN202010175551A CN112300099A CN 112300099 A CN112300099 A CN 112300099A CN 202010175551 A CN202010175551 A CN 202010175551A CN 112300099 A CN112300099 A CN 112300099A
- Authority
- CN
- China
- Prior art keywords
- alkyl
- radical
- group
- cycloalkyl
- substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 54
- 229940079593 drug Drugs 0.000 title claims abstract description 46
- 238000002360 preparation method Methods 0.000 title claims abstract description 39
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 16
- 150000001875 compounds Chemical class 0.000 claims abstract description 70
- 150000003839 salts Chemical class 0.000 claims abstract description 23
- 239000000126 substance Substances 0.000 claims abstract description 15
- -1 C2-40Alkynyl Chemical class 0.000 claims description 100
- 150000003254 radicals Chemical class 0.000 claims description 75
- 229920001223 polyethylene glycol Polymers 0.000 claims description 51
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 38
- 239000002202 Polyethylene glycol Substances 0.000 claims description 33
- 229960001592 paclitaxel Drugs 0.000 claims description 33
- 229960003957 dexamethasone Drugs 0.000 claims description 31
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 30
- 125000000623 heterocyclic group Chemical group 0.000 claims description 30
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 27
- 229930012538 Paclitaxel Natural products 0.000 claims description 26
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 claims description 22
- 125000001072 heteroaryl group Chemical group 0.000 claims description 21
- 229940123237 Taxane Drugs 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 18
- 229960002555 zidovudine Drugs 0.000 claims description 16
- 229960001057 paliperidone Drugs 0.000 claims description 15
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims description 15
- PMXMIIMHBWHSKN-UHFFFAOYSA-N 3-{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl}-9-hydroxy-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCC(O)C4=NC=3C)=NOC2=C1 PMXMIIMHBWHSKN-UHFFFAOYSA-N 0.000 claims description 14
- 125000000217 alkyl group Chemical group 0.000 claims description 14
- BMQGVNUXMIRLCK-OAGWZNDDSA-N cabazitaxel Chemical compound O([C@H]1[C@@H]2[C@]3(OC(C)=O)CO[C@@H]3C[C@@H]([C@]2(C(=O)[C@H](OC)C2=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=3C=CC=CC=3)C[C@]1(O)C2(C)C)C)OC)C(=O)C1=CC=CC=C1 BMQGVNUXMIRLCK-OAGWZNDDSA-N 0.000 claims description 14
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 14
- 125000006651 (C3-C20) cycloalkyl group Chemical group 0.000 claims description 13
- 229960001573 cabazitaxel Drugs 0.000 claims description 13
- 229960002930 sirolimus Drugs 0.000 claims description 13
- 229910052794 bromium Inorganic materials 0.000 claims description 12
- 229910052801 chlorine Inorganic materials 0.000 claims description 12
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims description 12
- 229960005420 etoposide Drugs 0.000 claims description 12
- 229910052731 fluorine Inorganic materials 0.000 claims description 12
- 229910052740 iodine Inorganic materials 0.000 claims description 12
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims description 12
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims description 12
- 229960002521 artenimol Drugs 0.000 claims description 11
- 229960003604 testosterone Drugs 0.000 claims description 11
- BJDCWCLMFKKGEE-ISOSDAIHSA-N artenimol Chemical compound C([C@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2O[C@H](O)[C@@H]4C BJDCWCLMFKKGEE-ISOSDAIHSA-N 0.000 claims description 10
- 229930016266 dihydroartemisinin Natural products 0.000 claims description 10
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 10
- 229960005277 gemcitabine Drugs 0.000 claims description 9
- 239000003862 glucocorticoid Substances 0.000 claims description 9
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 claims description 9
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 8
- 229960000853 abiraterone Drugs 0.000 claims description 8
- 229960002258 fulvestrant Drugs 0.000 claims description 8
- 229950010152 halofuginone Drugs 0.000 claims description 8
- 150000003180 prostaglandins Chemical class 0.000 claims description 8
- LGZKGOGODCLQHG-CYBMUJFWSA-N 5-[(2r)-2-hydroxy-2-(3,4,5-trimethoxyphenyl)ethyl]-2-methoxyphenol Chemical compound C1=C(O)C(OC)=CC=C1C[C@@H](O)C1=CC(OC)=C(OC)C(OC)=C1 LGZKGOGODCLQHG-CYBMUJFWSA-N 0.000 claims description 7
- FJHBVJOVLFPMQE-QFIPXVFZSA-N 7-Ethyl-10-Hydroxy-Camptothecin Chemical compound C1=C(O)C=C2C(CC)=C(CN3C(C4=C([C@@](C(=O)OC4)(O)CC)C=C33)=O)C3=NC2=C1 FJHBVJOVLFPMQE-QFIPXVFZSA-N 0.000 claims description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 7
- VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 claims description 7
- GZOSMCIZMLWJML-VJLLXTKPSA-N abiraterone Chemical compound C([C@H]1[C@H]2[C@@H]([C@]3(CC[C@H](O)CC3=CC2)C)CC[C@@]11C)C=C1C1=CC=CN=C1 GZOSMCIZMLWJML-VJLLXTKPSA-N 0.000 claims description 7
- 239000003443 antiviral agent Substances 0.000 claims description 7
- LGZKGOGODCLQHG-UHFFFAOYSA-N combretastatin Natural products C1=C(O)C(OC)=CC=C1CC(O)C1=CC(OC)=C(OC)C(OC)=C1 LGZKGOGODCLQHG-UHFFFAOYSA-N 0.000 claims description 7
- 125000001424 substituent group Chemical group 0.000 claims description 7
- 229960004458 tafluprost Drugs 0.000 claims description 7
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 6
- 229960003668 docetaxel Drugs 0.000 claims description 6
- 150000002170 ethers Chemical class 0.000 claims description 6
- 239000002777 nucleoside Substances 0.000 claims description 6
- 150000003833 nucleoside derivatives Chemical class 0.000 claims description 6
- 150000003505 terpenes Chemical class 0.000 claims description 6
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims description 5
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 5
- YGACXVRLDHEXKY-WXRXAMBDSA-N O[C@H](C[C@H]1c2c(cccc2F)-c2cncn12)[C@H]1CC[C@H](O)CC1 Chemical compound O[C@H](C[C@H]1c2c(cccc2F)-c2cncn12)[C@H]1CC[C@H](O)CC1 YGACXVRLDHEXKY-WXRXAMBDSA-N 0.000 claims description 5
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 claims description 5
- 150000001346 alkyl aryl ethers Chemical class 0.000 claims description 5
- BLUAFEHZUWYNDE-NNWCWBAJSA-N artemisinin Chemical class C([C@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2OC(=O)[C@@H]4C BLUAFEHZUWYNDE-NNWCWBAJSA-N 0.000 claims description 5
- 201000010099 disease Diseases 0.000 claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims description 5
- 229910052739 hydrogen Inorganic materials 0.000 claims description 5
- 239000003112 inhibitor Substances 0.000 claims description 5
- DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 claims description 5
- 229960003086 naltrexone Drugs 0.000 claims description 5
- 229960003179 rotigotine Drugs 0.000 claims description 5
- KFQYTPMOWPVWEJ-INIZCTEOSA-N rotigotine Chemical compound CCCN([C@@H]1CC2=CC=CC(O)=C2CC1)CCC1=CC=CS1 KFQYTPMOWPVWEJ-INIZCTEOSA-N 0.000 claims description 5
- 229960002855 simvastatin Drugs 0.000 claims description 5
- 229960001967 tacrolimus Drugs 0.000 claims description 5
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 claims description 5
- WSNODXPBBALQOF-VEJSHDCNSA-N tafluprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\C(F)(F)COC1=CC=CC=C1 WSNODXPBBALQOF-VEJSHDCNSA-N 0.000 claims description 5
- PAJMKGZZBBTTOY-ZFORQUDYSA-N treprostinil Chemical compound C1=CC=C(OCC(O)=O)C2=C1C[C@@H]1[C@@H](CC[C@@H](O)CCCCC)[C@H](O)C[C@@H]1C2 PAJMKGZZBBTTOY-ZFORQUDYSA-N 0.000 claims description 5
- 229960005032 treprostinil Drugs 0.000 claims description 5
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 claims description 4
- 239000003242 anti bacterial agent Substances 0.000 claims description 4
- LVASCWIMLIKXLA-LSDHHAIUSA-N halofuginone Chemical compound O[C@@H]1CCCN[C@H]1CC(=O)CN1C(=O)C2=CC(Cl)=C(Br)C=C2N=C1 LVASCWIMLIKXLA-LSDHHAIUSA-N 0.000 claims description 4
- 229910052736 halogen Inorganic materials 0.000 claims description 4
- 150000002367 halogens Chemical class 0.000 claims description 4
- 125000005844 heterocyclyloxy group Chemical group 0.000 claims description 4
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims description 4
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 claims description 4
- 229940037128 systemic glucocorticoids Drugs 0.000 claims description 4
- BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 claims description 3
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 claims description 3
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 claims description 3
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 claims description 3
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims description 3
- XQSPYNMVSIKCOC-NTSWFWBYSA-N Emtricitabine Chemical compound C1=C(F)C(N)=NC(=O)N1[C@H]1O[C@@H](CO)SC1 XQSPYNMVSIKCOC-NTSWFWBYSA-N 0.000 claims description 3
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 claims description 3
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 claims description 3
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 claims description 3
- 229920001244 Poly(D,L-lactide) Polymers 0.000 claims description 3
- WREGKURFCTUGRC-POYBYMJQSA-N Zalcitabine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)CC1 WREGKURFCTUGRC-POYBYMJQSA-N 0.000 claims description 3
- 229960004150 aciclovir Drugs 0.000 claims description 3
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 claims description 3
- 230000000202 analgesic effect Effects 0.000 claims description 3
- 229940088710 antibiotic agent Drugs 0.000 claims description 3
- 230000003115 biocidal effect Effects 0.000 claims description 3
- 229960004117 capecitabine Drugs 0.000 claims description 3
- 229960000684 cytarabine Drugs 0.000 claims description 3
- 229960004679 doxorubicin Drugs 0.000 claims description 3
- 229960000366 emtricitabine Drugs 0.000 claims description 3
- 229960005309 estradiol Drugs 0.000 claims description 3
- 229930182833 estradiol Natural products 0.000 claims description 3
- 229960002568 ethinylestradiol Drugs 0.000 claims description 3
- 229960000961 floxuridine Drugs 0.000 claims description 3
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 claims description 3
- 229960002963 ganciclovir Drugs 0.000 claims description 3
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 claims description 3
- 125000005553 heteroaryloxy group Chemical group 0.000 claims description 3
- 229960004716 idoxuridine Drugs 0.000 claims description 3
- 229960001627 lamivudine Drugs 0.000 claims description 3
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 claims description 3
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 claims description 3
- 229960004844 lovastatin Drugs 0.000 claims description 3
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 229960003962 trifluridine Drugs 0.000 claims description 3
- VSQQQLOSPVPRAZ-RRKCRQDMSA-N trifluridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(C(F)(F)F)=C1 VSQQQLOSPVPRAZ-RRKCRQDMSA-N 0.000 claims description 3
- 229960000523 zalcitabine Drugs 0.000 claims description 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 2
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- JAQUASYNZVUNQP-USXIJHARSA-N Levorphanol Chemical compound C1C2=CC=C(O)C=C2[C@]23CCN(C)[C@H]1[C@@H]2CCCC3 JAQUASYNZVUNQP-USXIJHARSA-N 0.000 claims description 2
- UQCNKQCJZOAFTQ-ISWURRPUSA-N Oxymorphone Chemical compound O([C@H]1C(CC[C@]23O)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O UQCNKQCJZOAFTQ-ISWURRPUSA-N 0.000 claims description 2
- 229940035676 analgesics Drugs 0.000 claims description 2
- 239000000730 antalgic agent Substances 0.000 claims description 2
- 229960002470 bimatoprost Drugs 0.000 claims description 2
- AQOKCDNYWBIDND-FTOWTWDKSA-N bimatoprost Chemical compound CCNC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)CCC1=CC=CC=C1 AQOKCDNYWBIDND-FTOWTWDKSA-N 0.000 claims description 2
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 claims description 2
- 229960001736 buprenorphine Drugs 0.000 claims description 2
- IFKLAQQSCNILHL-QHAWAJNXSA-N butorphanol Chemical compound N1([C@@H]2CC3=CC=C(C=C3[C@@]3([C@]2(CCCC3)O)CC1)O)CC1CCC1 IFKLAQQSCNILHL-QHAWAJNXSA-N 0.000 claims description 2
- 229960001113 butorphanol Drugs 0.000 claims description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
- 229960000980 entecavir Drugs 0.000 claims description 2
- YXPVEXCTPGULBZ-WQYNNSOESA-N entecavir hydrate Chemical compound O.C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)C1=C YXPVEXCTPGULBZ-WQYNNSOESA-N 0.000 claims description 2
- 229960000890 hydrocortisone Drugs 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims description 2
- WVLOADHCBXTIJK-YNHQPCIGSA-N hydromorphone Chemical compound O([C@H]1C(CC[C@H]23)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O WVLOADHCBXTIJK-YNHQPCIGSA-N 0.000 claims description 2
- 229960001410 hydromorphone Drugs 0.000 claims description 2
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims description 2
- XXUPXHKCPIKWLR-JHUOEJJVSA-N isopropyl unoprostone Chemical compound CCCCCCCC(=O)CC[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(=O)OC(C)C XXUPXHKCPIKWLR-JHUOEJJVSA-N 0.000 claims description 2
- 229960001160 latanoprost Drugs 0.000 claims description 2
- GGXICVAJURFBLW-CEYXHVGTSA-N latanoprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1 GGXICVAJURFBLW-CEYXHVGTSA-N 0.000 claims description 2
- 229960003406 levorphanol Drugs 0.000 claims description 2
- NETZHAKZCGBWSS-CEDHKZHLSA-N nalbuphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]1(O)CC[C@@H]3O)CN2CC1CCC1 NETZHAKZCGBWSS-CEDHKZHLSA-N 0.000 claims description 2
- 229960000805 nalbuphine Drugs 0.000 claims description 2
- 229960005118 oxymorphone Drugs 0.000 claims description 2
- 230000000704 physical effect Effects 0.000 claims description 2
- 229960004618 prednisone Drugs 0.000 claims description 2
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims description 2
- 230000008569 process Effects 0.000 claims description 2
- 229960004556 tenofovir Drugs 0.000 claims description 2
- VCMJCVGFSROFHV-WZGZYPNHSA-N tenofovir disoproxil fumarate Chemical compound OC(=O)\C=C\C(O)=O.N1=CN=C2N(C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)C=NC2=C1N VCMJCVGFSROFHV-WZGZYPNHSA-N 0.000 claims description 2
- 229960002368 travoprost Drugs 0.000 claims description 2
- MKPLKVHSHYCHOC-AHTXBMBWSA-N travoprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)COC1=CC=CC(C(F)(F)F)=C1 MKPLKVHSHYCHOC-AHTXBMBWSA-N 0.000 claims description 2
- 229950008081 unoprostone isopropyl Drugs 0.000 claims description 2
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims 1
- 239000005977 Ethylene Substances 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 description 97
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 90
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 71
- 229940002612 prodrug Drugs 0.000 description 69
- 239000000651 prodrug Substances 0.000 description 69
- 239000002105 nanoparticle Substances 0.000 description 51
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 49
- 238000002347 injection Methods 0.000 description 47
- 239000007924 injection Substances 0.000 description 47
- 229940090044 injection Drugs 0.000 description 45
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 40
- 239000000243 solution Substances 0.000 description 36
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 35
- JXTHNDFMNIQAHM-UHFFFAOYSA-N dichloroacetic acid Chemical compound OC(=O)C(Cl)Cl JXTHNDFMNIQAHM-UHFFFAOYSA-N 0.000 description 32
- 230000000694 effects Effects 0.000 description 31
- QWOJMRHUQHTCJG-UHFFFAOYSA-N CC([CH2-])=O Chemical compound CC([CH2-])=O QWOJMRHUQHTCJG-UHFFFAOYSA-N 0.000 description 30
- 238000003786 synthesis reaction Methods 0.000 description 29
- 238000005160 1H NMR spectroscopy Methods 0.000 description 28
- 239000008280 blood Substances 0.000 description 28
- 210000004369 blood Anatomy 0.000 description 28
- 238000012360 testing method Methods 0.000 description 28
- 241000700159 Rattus Species 0.000 description 27
- 230000015572 biosynthetic process Effects 0.000 description 26
- 238000003756 stirring Methods 0.000 description 25
- 230000007062 hydrolysis Effects 0.000 description 23
- 238000006460 hydrolysis reaction Methods 0.000 description 23
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 22
- 229960005215 dichloroacetic acid Drugs 0.000 description 22
- 125000004432 carbon atom Chemical group C* 0.000 description 21
- 239000000203 mixture Substances 0.000 description 20
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 20
- 206010028980 Neoplasm Diseases 0.000 description 19
- 238000010898 silica gel chromatography Methods 0.000 description 19
- 229910052757 nitrogen Inorganic materials 0.000 description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 18
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 15
- 235000019441 ethanol Nutrition 0.000 description 15
- 239000002994 raw material Substances 0.000 description 15
- 239000007787 solid Substances 0.000 description 15
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 14
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 14
- 239000002159 nanocrystal Substances 0.000 description 13
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 12
- 229920001427 mPEG Polymers 0.000 description 12
- 239000000693 micelle Substances 0.000 description 12
- 238000012544 monitoring process Methods 0.000 description 12
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 12
- FKTLISWEAOSVBS-UHFFFAOYSA-N 2-prop-1-en-2-yloxyprop-1-ene Chemical compound CC(=C)OC(C)=C FKTLISWEAOSVBS-UHFFFAOYSA-N 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 11
- 238000001914 filtration Methods 0.000 description 11
- 238000000926 separation method Methods 0.000 description 11
- 239000002904 solvent Substances 0.000 description 11
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 10
- 238000001727 in vivo Methods 0.000 description 10
- 229920006395 saturated elastomer Polymers 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 125000002619 bicyclic group Chemical group 0.000 description 9
- 238000001035 drying Methods 0.000 description 9
- 238000009472 formulation Methods 0.000 description 9
- 238000011580 nude mouse model Methods 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 239000012265 solid product Substances 0.000 description 9
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 9
- LFYTYTCSWRUXKW-UHFFFAOYSA-N 1-prop-1-en-2-yloxyoctadecane Chemical compound CCCCCCCCCCCCCCCCCCOC(C)=C LFYTYTCSWRUXKW-UHFFFAOYSA-N 0.000 description 8
- 238000010171 animal model Methods 0.000 description 8
- 239000000872 buffer Substances 0.000 description 8
- 239000003054 catalyst Substances 0.000 description 8
- 150000002430 hydrocarbons Chemical group 0.000 description 8
- 238000010255 intramuscular injection Methods 0.000 description 8
- 239000007927 intramuscular injection Substances 0.000 description 8
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 8
- 238000010791 quenching Methods 0.000 description 8
- 238000005406 washing Methods 0.000 description 8
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
- 239000002253 acid Substances 0.000 description 7
- 239000007864 aqueous solution Substances 0.000 description 7
- 238000004128 high performance liquid chromatography Methods 0.000 description 7
- 125000002950 monocyclic group Chemical group 0.000 description 7
- 239000012074 organic phase Substances 0.000 description 7
- 239000000741 silica gel Substances 0.000 description 7
- 229910002027 silica gel Inorganic materials 0.000 description 7
- 239000004215 Carbon black (E152) Substances 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 241000699660 Mus musculus Species 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- 230000000259 anti-tumor effect Effects 0.000 description 6
- 235000012000 cholesterol Nutrition 0.000 description 6
- 229930195733 hydrocarbon Natural products 0.000 description 6
- 210000001503 joint Anatomy 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 238000010561 standard procedure Methods 0.000 description 6
- PENKKVBJNTYHDH-UHFFFAOYSA-N 1-prop-1-en-2-yloxyhexane Chemical compound CCCCCCOC(C)=C PENKKVBJNTYHDH-UHFFFAOYSA-N 0.000 description 5
- 206010003246 arthritis Diseases 0.000 description 5
- 125000003118 aryl group Chemical group 0.000 description 5
- 238000004440 column chromatography Methods 0.000 description 5
- VQODGRNSFPNSQE-CXSFZGCWSA-N dexamethasone phosphate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)COP(O)(O)=O)(O)[C@@]1(C)C[C@@H]2O VQODGRNSFPNSQE-CXSFZGCWSA-N 0.000 description 5
- 150000002148 esters Chemical class 0.000 description 5
- 238000002649 immunization Methods 0.000 description 5
- 230000003053 immunization Effects 0.000 description 5
- 238000010253 intravenous injection Methods 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 210000003462 vein Anatomy 0.000 description 5
- WEVYAHXRMPXWCK-MICDWDOJSA-N 2-deuterioacetonitrile Chemical compound [2H]CC#N WEVYAHXRMPXWCK-MICDWDOJSA-N 0.000 description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
- 241000283977 Oryctolagus Species 0.000 description 4
- PTKFEDGHUVZLPL-LLUYWJARSA-N Pectenotoxin 2 Chemical compound O[C@@H]1[C@H](C)CCO[C@]1(O)[C@H]1O[C@@H]2/C=C/C(/C)=C/[C@H](C)C[C@](C)(O3)CC[C@@H]3[C@](O3)(O4)CC[C@@]3(C)C[C@@H]4[C@@H](O3)C(=O)C[C@]3(C)[C@@H](O)[C@@H](O3)CC[C@@]3(O3)CCC[C@H]3[C@@H](C)C(=O)O[C@@H]2C1 PTKFEDGHUVZLPL-LLUYWJARSA-N 0.000 description 4
- 108010087230 Sincalide Proteins 0.000 description 4
- QYKIQEUNHZKYBP-UHFFFAOYSA-N Vinyl ether Chemical class C=COC=C QYKIQEUNHZKYBP-UHFFFAOYSA-N 0.000 description 4
- 239000008346 aqueous phase Substances 0.000 description 4
- 239000012298 atmosphere Substances 0.000 description 4
- 238000010609 cell counting kit-8 assay Methods 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 230000000857 drug effect Effects 0.000 description 4
- 238000002296 dynamic light scattering Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 125000005842 heteroatom Chemical group 0.000 description 4
- FVDRFBGMOWJEOR-UHFFFAOYSA-N hexadecan-2-ol Chemical compound CCCCCCCCCCCCCCC(C)O FVDRFBGMOWJEOR-UHFFFAOYSA-N 0.000 description 4
- 230000005917 in vivo anti-tumor Effects 0.000 description 4
- 230000004410 intraocular pressure Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- ZDYVRSLAEXCVBX-UHFFFAOYSA-N pyridinium p-toluenesulfonate Chemical compound C1=CC=[NH+]C=C1.CC1=CC=C(S([O-])(=O)=O)C=C1 ZDYVRSLAEXCVBX-UHFFFAOYSA-N 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 4
- 230000000087 stabilizing effect Effects 0.000 description 4
- 229910052717 sulfur Inorganic materials 0.000 description 4
- BFKJFAAPBSQJPD-UHFFFAOYSA-N tetrafluoroethene Chemical group FC(F)=C(F)F BFKJFAAPBSQJPD-UHFFFAOYSA-N 0.000 description 4
- 238000006276 transfer reaction Methods 0.000 description 4
- 238000004627 transmission electron microscopy Methods 0.000 description 4
- 230000004614 tumor growth Effects 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical group C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 3
- LVNGJLRDBYCPGB-LDLOPFEMSA-N (R)-1,2-distearoylphosphatidylethanolamine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[NH3+])OC(=O)CCCCCCCCCCCCCCCCC LVNGJLRDBYCPGB-LDLOPFEMSA-N 0.000 description 3
- SIZDIMDMQQFWLM-UHFFFAOYSA-N 1-methoxyethenylbenzene Chemical compound COC(=C)C1=CC=CC=C1 SIZDIMDMQQFWLM-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 125000005605 benzo group Chemical group 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- UHOVQNZJYSORNB-MICDWDOJSA-N deuteriobenzene Chemical compound [2H]C1=CC=CC=C1 UHOVQNZJYSORNB-MICDWDOJSA-N 0.000 description 3
- 229960002344 dexamethasone sodium phosphate Drugs 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 230000003301 hydrolyzing effect Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- 210000003141 lower extremity Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000002547 new drug Substances 0.000 description 3
- 239000012454 non-polar solvent Substances 0.000 description 3
- 125000001117 oleyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
- 229920000053 polysorbate 80 Polymers 0.000 description 3
- 125000006239 protecting group Chemical group 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 3
- 238000009987 spinning Methods 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 238000005199 ultracentrifugation Methods 0.000 description 3
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 3
- 229920002554 vinyl polymer Polymers 0.000 description 3
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 2
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 description 2
- 125000006714 (C3-C10) heterocyclyl group Chemical group 0.000 description 2
- 125000006708 (C5-C14) heteroaryl group Chemical group 0.000 description 2
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- KWOLFJPFCHCOCG-UHFFFAOYSA-N Acetophenone Chemical compound CC(=O)C1=CC=CC=C1 KWOLFJPFCHCOCG-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 description 2
- 125000005865 C2-C10alkynyl group Chemical group 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical class CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- CRZQGDNQQAALAY-UHFFFAOYSA-N Methyl benzeneacetate Chemical compound COC(=O)CC1=CC=CC=C1 CRZQGDNQQAALAY-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- MCMNRKCIXSYSNV-UHFFFAOYSA-N Zirconium dioxide Chemical compound O=[Zr]=O MCMNRKCIXSYSNV-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- 125000000304 alkynyl group Chemical group 0.000 description 2
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 2
- 210000000544 articulatio talocruralis Anatomy 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- UHOVQNZJYSORNB-MZWXYZOWSA-N benzene-d6 Chemical compound [2H]C1=C([2H])C([2H])=C([2H])C([2H])=C1[2H] UHOVQNZJYSORNB-MZWXYZOWSA-N 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- JJNHBFYGCSOONU-UHFFFAOYSA-M carbanide;cyclopenta-1,3-diene;dimethylaluminum;titanium(4+);chloride Chemical compound [CH3-].[Ti+3]Cl.C[Al]C.C=1C=C[CH-]C=1.C=1C=C[CH-]C=1 JJNHBFYGCSOONU-UHFFFAOYSA-M 0.000 description 2
- 150000001721 carbon Chemical group 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000012230 colorless oil Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 238000002784 cytotoxicity assay Methods 0.000 description 2
- 231100000263 cytotoxicity test Toxicity 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 229960004833 dexamethasone phosphate Drugs 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 238000006073 displacement reaction Methods 0.000 description 2
- 238000009509 drug development Methods 0.000 description 2
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 2
- 229940075383 etoposide injection Drugs 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000012737 fresh medium Substances 0.000 description 2
- 238000005984 hydrogenation reaction Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000012263 liquid product Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen(.) Chemical compound [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- SJWFXCIHNDVPSH-UHFFFAOYSA-N octan-2-ol Chemical compound CCCCCCC(C)O SJWFXCIHNDVPSH-UHFFFAOYSA-N 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 229940055577 oleyl alcohol Drugs 0.000 description 2
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 2
- 125000006413 ring segment Chemical group 0.000 description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 150000003333 secondary alcohols Chemical class 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 125000001544 thienyl group Chemical group 0.000 description 2
- 229910052719 titanium Inorganic materials 0.000 description 2
- 239000010936 titanium Substances 0.000 description 2
- 229940035307 toposar Drugs 0.000 description 2
- FTVLMFQEYACZNP-UHFFFAOYSA-N trimethylsilyl trifluoromethanesulfonate Chemical compound C[Si](C)(C)OS(=O)(=O)C(F)(F)F FTVLMFQEYACZNP-UHFFFAOYSA-N 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- MJWYCUZCRGLCBD-BGZMIMFDSA-N (4s)-4-amino-5-[[(2s)-1-[[(2s)-1-[[(2s,3s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-oxopentanoic acid Chemical group OC[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCC(O)=O MJWYCUZCRGLCBD-BGZMIMFDSA-N 0.000 description 1
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- 125000005918 1,2-dimethylbutyl group Chemical group 0.000 description 1
- 125000006218 1-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- BFUUJUGQJUTPAF-UHFFFAOYSA-N 2-(3-amino-4-propoxybenzoyl)oxyethyl-diethylazanium;chloride Chemical compound [Cl-].CCCOC1=CC=C(C(=O)OCC[NH+](CC)CC)C=C1N BFUUJUGQJUTPAF-UHFFFAOYSA-N 0.000 description 1
- 125000006176 2-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 description 1
- DILJBLUOUOALOF-UHFFFAOYSA-N 2-methoxyoctane Chemical compound CCCCCCC(C)OC DILJBLUOUOALOF-UHFFFAOYSA-N 0.000 description 1
- YOWQWFMSQCOSBA-UHFFFAOYSA-N 2-methoxypropene Chemical compound COC(C)=C YOWQWFMSQCOSBA-UHFFFAOYSA-N 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000003542 3-methylbutan-2-yl group Chemical group [H]C([H])([H])C([H])(*)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000005917 3-methylpentyl group Chemical group 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- VOBDXTSTTMAKHK-VHDCPBDGSA-N 3870-07-3 Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)COC(=O)C)[C@@]1(C)C[C@@H]2O VOBDXTSTTMAKHK-VHDCPBDGSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 125000003358 C2-C20 alkenyl group Chemical group 0.000 description 1
- 125000005915 C6-C14 aryl group Chemical group 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000000503 Collagen Type II Human genes 0.000 description 1
- 108010041390 Collagen Type II Proteins 0.000 description 1
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 229940124602 FDA-approved drug Drugs 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 210000003423 ankle Anatomy 0.000 description 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
- 229940121357 antivirals Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 125000004931 azocinyl group Chemical group N1=C(C=CC=CC=C1)* 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- ACBQROXDOHKANW-UHFFFAOYSA-N bis(4-nitrophenyl) carbonate Chemical compound C1=CC([N+](=O)[O-])=CC=C1OC(=O)OC1=CC=C([N+]([O-])=O)C=C1 ACBQROXDOHKANW-UHFFFAOYSA-N 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000037182 bone density Effects 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical group 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 210000000795 conjunctiva Anatomy 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- HPXRVTGHNJAIIH-UHFFFAOYSA-N cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000006547 cyclononyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 125000004855 decalinyl group Chemical group C1(CCCC2CCCCC12)* 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 125000005959 diazepanyl group Chemical group 0.000 description 1
- 125000005045 dihydroisoquinolinyl group Chemical group C1(NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000005046 dihydronaphthyl group Chemical group 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 125000005883 dithianyl group Chemical group 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000002905 effect on arthritis Effects 0.000 description 1
- 125000006575 electron-withdrawing group Chemical group 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 230000007071 enzymatic hydrolysis Effects 0.000 description 1
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- 239000001307 helium Substances 0.000 description 1
- 229910052734 helium Inorganic materials 0.000 description 1
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
- 125000005549 heteroarylene group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 210000000548 hind-foot Anatomy 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 229910052743 krypton Inorganic materials 0.000 description 1
- DNNSSWSSYDEUBZ-UHFFFAOYSA-N krypton atom Chemical compound [Kr] DNNSSWSSYDEUBZ-UHFFFAOYSA-N 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- QLIIKPVHVRXHRI-CXSFZGCWSA-N mometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)C[C@@H]2O QLIIKPVHVRXHRI-CXSFZGCWSA-N 0.000 description 1
- 229960001664 mometasone Drugs 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 229910052754 neon Inorganic materials 0.000 description 1
- GKAOGPIIYCISHV-UHFFFAOYSA-N neon atom Chemical compound [Ne] GKAOGPIIYCISHV-UHFFFAOYSA-N 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- QXYWIOWTBOREMG-UHFFFAOYSA-N nonadecan-2-ol Chemical compound CCCCCCCCCCCCCCCCCC(C)O QXYWIOWTBOREMG-UHFFFAOYSA-N 0.000 description 1
- 230000004493 normal intraocular pressure Effects 0.000 description 1
- 230000005311 nuclear magnetism Effects 0.000 description 1
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 1
- 238000000399 optical microscopy Methods 0.000 description 1
- 229940124585 oral penicillin Drugs 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- YWWARDMVSMPOLR-UHFFFAOYSA-M oxolane;tetrabutylazanium;fluoride Chemical compound [F-].C1CCOC1.CCCC[N+](CCCC)(CCCC)CCCC YWWARDMVSMPOLR-UHFFFAOYSA-M 0.000 description 1
- NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 125000001791 phenazinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3N=C12)* 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 1
- 125000001644 phenoxazinyl group Chemical group C1(=CC=CC=2OC3=CC=CC=C3NC12)* 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229960001371 proparacaine hydrochloride Drugs 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 125000005551 pyridylene group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000001422 pyrrolinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000002390 rotary evaporation Methods 0.000 description 1
- 229940126586 small molecule drug Drugs 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 1
- 229960000894 sulindac Drugs 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000005329 tetralinyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000005556 thienylene group Chemical group 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 125000005455 trithianyl group Chemical group 0.000 description 1
- 239000013585 weight reducing agent Substances 0.000 description 1
- 229910052724 xenon Inorganic materials 0.000 description 1
- FHNFHKCVQCLJFQ-UHFFFAOYSA-N xenon atom Chemical compound [Xe] FHNFHKCVQCLJFQ-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
- C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/765—Polymers containing oxygen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C43/00—Ethers; Compounds having groups, groups or groups
- C07C43/02—Ethers
- C07C43/235—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring and to a carbon atom of a ring other than a six-membered aromatic ring
- C07C43/243—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring and to a carbon atom of a ring other than a six-membered aromatic ring having unsaturation outside the six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/30—Oxygen atoms, e.g. delta-lactones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
- C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D411/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/12—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
- C07D493/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C07H15/24—Condensed ring systems having three or more rings
- C07H15/252—Naphthacene radicals, e.g. daunomycins, adriamycins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/067—Pyrimidine radicals with ribosyl as the saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/073—Pyrimidine radicals with 2-deoxyribosyl as the saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
- C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
- C07J5/0046—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
- C07J5/0061—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa substituted in position 16
- C07J5/0069—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa substituted in position 16 by a saturated or unsaturated hydrocarbon group
- C07J5/0076—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa substituted in position 16 by a saturated or unsaturated hydrocarbon group by an alkyl group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
- C08G65/32—Polymers modified by chemical after-treatment
- C08G65/329—Polymers modified by chemical after-treatment with organic compounds
- C08G65/331—Polymers modified by chemical after-treatment with organic compounds containing oxygen
- C08G65/3311—Polymers modified by chemical after-treatment with organic compounds containing oxygen containing a hydroxy group
- C08G65/3314—Polymers modified by chemical after-treatment with organic compounds containing oxygen containing a hydroxy group cyclic
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
- C08G65/32—Polymers modified by chemical after-treatment
- C08G65/329—Polymers modified by chemical after-treatment with organic compounds
- C08G65/331—Polymers modified by chemical after-treatment with organic compounds containing oxygen
- C08G65/332—Polymers modified by chemical after-treatment with organic compounds containing oxygen containing carboxyl groups, or halides, or esters thereof
- C08G65/3328—Polymers modified by chemical after-treatment with organic compounds containing oxygen containing carboxyl groups, or halides, or esters thereof heterocyclic
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
- C08G65/32—Polymers modified by chemical after-treatment
- C08G65/329—Polymers modified by chemical after-treatment with organic compounds
- C08G65/333—Polymers modified by chemical after-treatment with organic compounds containing nitrogen
- C08G65/33396—Polymers modified by chemical after-treatment with organic compounds containing nitrogen having oxygen in addition to nitrogen
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Polymers & Plastics (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to a ketal derivative of a medicament, a preparation method, a pharmaceutical composition and application thereof. Wherein the ketal derivative comprises a compound represented by the following formula (I), a racemate, a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof:the ketal derivatives of the invention can significantly improve the physical, chemical and/or pharmaceutical properties of the original starting drug.
Description
The application requires that the patent application number is 201910713864.0, which is submitted to the intellectual property office of China in 2019, 8, 2, and the invention name is ' ketal derivative of medicine and preparation method, pharmaceutical composition and application thereof ' priority of prior application '. The entire disclosure of this application is incorporated by reference into this application.
Technical Field
The invention belongs to the technical field of prodrug compounds, and particularly relates to a ketal derivative of a medicament, a preparation method, a pharmaceutical composition and application thereof.
Background
Prodrugs are an important class of derivatives of pharmaceutical compounds. Prodrug derivatives have been reported to include carrier prodrugs and biological prodrugs. Wherein, carrier prodrug means that the active compound is combined with the carrier with the transportation function through covalent bond, and the carrier is removed through simple hydrolysis in vivo to exert pharmacological action by the active compound. Carrier prodrugs tend to be less active or inactive than the parent compound. The structure of the carrier is mostly lipophilic, and is required to be harmless to organisms and to release the active compound in a timely manner. The oral penicillin drugs in the market often adopt a carrier prodrug mode to improve the bioavailability; biological prodrugs differ from carrier prodrugs in that the active substance does not bind to the carrier temporarily, but rather acts by changing its molecular structure. Biological prodrugs are generally inactive per se, but active as in vivo metabolites. Some non-steroidal anti-inflammatory drugs (e.g., sulindac) have been designed based on this concept.
As prodrug derivatives are widely used in improved drug development, their position in new drug development is also becoming more important. Statistically, in year 2008-2017, a total of 30 U.S. FDA-approved new drugs belong to prodrug compounds, which are about 10% of the total amount of FDA-approved drugs. Among the us FDA-approved new drugs in 2017, the prodrug compound ratio was about 17% (nat. rev. drug discov.2018,17(8): 559-.
Among the drug compounds, the drugs containing hydroxyl groups (including phenolic, carboxylic and alcoholic hydroxyl groups) account for about 51% of small molecule drugs (https:// pubs. ac. org. ccidex. cn/doi/pdf/10.1021/cc9800071), which includes most molecules of several major classes of drugs such as taxanes, glucocorticoids, prostaglandin analogs, antibiotics, antivirals and terpenes. Ester formation is the most common modification in prodrug design. Of the prodrugs that are marketed, approximately 49% are active by enzymatic hydrolysis. For example, the hydroxyl group of poorly water soluble drugs is often designed as phosphate to improve their water solubility, more suitable for oral or injectable administration. Carbonate and carbamate prodrugs of hydroxyl groups may be more stable to enzymes.
Chinese patent applications CN107353399A and CN103285400A disclose acid-sensitive polymeric prodrugs in which an acetal bond is used to link a drug molecule to a polymer to modify the release of the drug molecule when circulating in vivo. However, the molecular fragments produced when their prodrugs are released may have certain properties that are not beneficial to humans, or their release characteristics in physiological or acidic environments in vivo remain to be further improved (Louse, Benoit, Mies J. Van Steenbergen, Lutz Nuhn, Martijn DP Risseuw, IZet Karaic, John wine, Large Van Calenbergh, Wim E. Hennink, and Bruno G.De Geest. "Micellar tablet-associated RAFT polymer conjugates with acid-sensitive detector." ACS. Macro Letters 6, 3(2017): 272; Zhai, Yingelei, XZhou, Lina Jia, Changze Mazeo, Yang, Hu hong, Hu Zhen, Weldu, Zhen Shu-7, polymeric PEG 9, polymeric primer, and primer.
To this end, there is a need for further development of new prodrugs that may facilitate the metabolism of the prodrug, improve the release characteristics, and/or reduce the physiological toxicity or other side effects of the molecules that they release.
Disclosure of Invention
In order to improve the technical problems, the present invention provides a compound represented by the following formula (I), a racemate, a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof:
wherein D is selected from the group consisting of a drug compound having at least one hydroxyl group, from which a hydrogen atom on one hydroxyl group has been removed;
R1selected from unsubstituted or optionally substituted by one, two or more RaSubstituted of the following groups: c1-40Alkyl radical, C3-20Cycloalkyl, 3-20 membered heterocyclyl, C6-20Aryl, 5-20 membered heteroaryl;
R2selected from or unsubstituted or optionally substituted by one, two or more RbSubstituted radicals-O-R4;
R3Selected from unsubstituted or optionally substituted by one, two or more RcSubstituted C1-40An alkyl group;
R4selected from substituents other than hydrogen;
each RaIndependently selected from halogen (such as F, Cl, Br, I), OH, SH, CN, N3Or unsubstituted or optionally substituted by one or more RbSubstituted of the following groups: c1-40Alkyl radical, C1-40Alkoxy radical, C2-40Alkenyl radical, C2-40Alkynyl, C3-20Cycloalkyl radical, C3-20Cycloalkyloxy, 3-20 membered heterocyclyl, 3-20 membered heterocyclyloxy, C6-20Aryl radical, C6-20Aryloxy, 5-20 membered heteroaryl, 5-20 membered heteroaryloxy, NRdRe、-CONRdRe、-C(O)YRf、-Y(O)CRf、-YP(O)(OM1)(OM2)、-YS(O)2OM3;
Each RbIndependently selected from F, Cl, Br, I, OH, SH, CN, N3Or unsubstituted or optionally substituted by one or more RcSubstituted of the following groups: c1-40Alkyl radical, C1-40Alkoxy radical, C2-40Alkenyl radical, C2-40Alkynyl, C3-20Cycloalkyl radical, C3-20Cycloalkyloxy, 3-20 membered heterocyclyl, 3-20 membered heterocyclyloxy, C6-20Aryl radical, C6-20Aryloxy, 5-20 membered heteroaryl, 5-20 membered heteroaryloxy, NRdRe、-CONRdRe、-C(O)YRf、-Y(O)CRf、-YP(O)(OM1)(OM2)、-YS(O)2OM3;
Each RcIndependently selected from F, Cl, Br, I, OH, SH, CN, N3Or unsubstituted or optionally substituted by one or more RaSubstituted of the following groups: c1-40Alkyl radical, C1-40Alkoxy radical, C2-40Alkenyl radical, C2-40Alkynyl, C3-20Cycloalkyl, 3-20 membered heterocyclyl, C6-20Aryl, 5-20 membered heteroaryl, NRdRe、-CONRdRe、-C(O)YRf、-Y(O)CRf、-YP(O)(OM1)(OM2)、-YS(O)2OM3;
Each RdAnd ReIndependently of one another, selected from H, or unsubstituted or optionally substituted by one or more RmSubstituted of the following groups: c1-40Alkyl radical, C2-40Alkenyl radical, C2-40Alkynyl, C3-20Cycloalkyl, 3-20 membered heterocyclyl, C6-20Aryl, 5-20 membered heteroaryl, -CONRfRg、-C(O)YRf、-Y(O)CRf、-YP(O)(OM1)(OM2)、-YS(O)2OM3;
Each RfAnd RgIndependently of one another, selected from H, or unsubstituted or optionally substituted by one or more RmSubstituted of the following groups: c1-40Alkyl radical, C2-40Alkenyl radical, C2-40Alkynyl, C3-20Cycloalkyl, COOH, 3-20 membered heterocyclyl, C6-20Aryl, 5-20 membered heteroaryl;
each RmIndependently selected from H, F, Cl, Br, I, OH, SH, CN, N3Or unsubstituted or optionally substituted by one or more RaSubstituted of the following groups: c1-40Alkyl radical, C1-40Alkoxy radical, C2-40Alkenyl radical, C2-40Alkynyl, C3-20Cycloalkyl, 3-20 membered heterocyclyl, C6-20Aryl, 5-20 membered heteroaryl, NRdRe、-CONRdRe、-C(O)YRf、Y(O)CRf、-YP(O)(OM1)(OM2)、-YS(O)2OM3;
Each Y is independently selected from the group consisting of a bond, -O-, -S-, or unsubstituted or optionally substituted with one or more Rasubstituted-NH-, C1-40Alkyl radical, C1-40Alkoxy radical, C3-20Cycloalkyl, 3-20 membered heterocyclyl, C6-20Aryl, 5-20 membered heteroaryl, - (CH)2CH2O)mWherein m is an integer of 0 or more, for example, an integer of 0 to 10;
M1、M2、M3independently of one another, selected from H, or unsubstituted or optionally substituted by one or more RaSubstituted C1-40An alkyl group.
According to an embodiment of the present invention, wherein D is selected from the group consisting of a pharmaceutical compound having at least one hydroxyl group, wherein the hydrogen atom of one of the hydroxyl groups of the pharmaceutical compound is removed, wherein the pharmaceutical compound having at least one hydroxyl group may be selected from the group consisting of, but not limited to, the following pharmaceutical compounds:
taxanes (e.g., paclitaxel, docetaxel, cabazitaxel);
glucocorticoids (e.g., hydrocortisone, dexamethasone, prednisone, triamcinolone acetonide acetate, mometasone, testosterone, estradiol, ethinyl estradiol, lineestrol);
prostaglandin analogs (e.g., tafluprost, latanoprost, travoprost, bimatoprost, unoprostone isopropyl ester);
paliperidone;
artemisinin analogs (e.g., dihydroartemisinin);
nucleoside analogs (gemcitabine, trifluridine, idoxuridine, floxuridine, capecitabine, zalcitabine, cytarabine);
antiviral drugs (ganciclovir, acyclovir, emtricitabine, zidovudine, lamivudine, tenofovir, entecavir);
antibiotics (doxorubicin);
naltrexone;
rotigotine;
rapamycin, tacrolimus;
treprostinil;
amshufaxin;
etoposide; halofuginone;
combretastatin;
SN-38;
rapamycin;
fulvestrant;
abiraterone;
statins (simvastatin and lovastatin);
analgesic drugs (buprenorphine, oxymorphone, nalbuphine, levorphanol, hydromorphone, butorphanol);
IDO inhibitor NLG 919; and
terpenoid drugs;
when the pharmaceutical compound containing at least one hydroxyl group comprises two or more hydroxyl groups, at least one other hydroxyl group in the group D may be further removed from a hydrogen atom and reacted with-CR1R2R3A group shown is bonded, wherein R1、R2、R3Which may be the same or different at each occurrence, independently of one another, have the definitions described above.
According to an embodiment of the invention, the pharmaceutical compound is selected from the group comprising, but not limited to, the following compounds containing at least one hydroxyl group: paclitaxel, docetaxel, cabazitaxel, dexamethasone, tafluprost, paliperidone, dihydroartemisinin, gemcitabine, zidovudine, testosterone, etoposide, NLG919, halofuginone, combretastatin, SN-38, rapamycin, fulvestrant, abiraterone, or simvastatin.
According to an embodiment of the invention, R1Can be selected from unsubstituted or optionally substituted by one, two or more RaSubstituted of the following groups: c1-6Alkyl radical, C3-6Cycloalkyl, 3-6 membered heterocyclyl, C6-10Aryl, 5-6 membered heteroaryl;
according to an embodiment of the invention, R3Selected from unsubstituted or optionally substituted by one, two or more RcSubstituted C1-6An alkyl group;
according to an embodiment of the invention, R4Is selected from C1-40Alkyl radical, C2-40Alkenyl radical, C3-20Cycloalkyl radical, C3-20Cycloalkenyl group, 3-20 membered heterocyclic group, C6-20Aryl, 5-20 membered heteroaryl, -C1-40alkyl-OC (O) -PEG, -C1-40alkyl-OC (O) -PEG-C1-40Alkyl, -C1-40alkyl-OC (O) -C1-40alkyl-C (O) -PDLLA-PEG, -C1-40alkyl-OC (O) -C1-40alkyl-C (O) -PDLLA-PEG-C1-40Alkyl, -C1-40alkyl-OC (O) -C1-40alkyl-C (O) - (O-C)1-40alkyl-CO)p-(O-C1-40Alkyl radical)q-C1-40Alkyl, -C1-40alkyl-OC (O) -C1-40alkyl-C (O) - (O-C)1-40alkyl-CO)p-(O-C1-40Alkyl radical)q-H、-C1-40alkyl-OCO2-(C1-40alkyl-O)r-C1-40Alkyl, -C1-40alkyl-OCO2-(C1-40alkyl-O)r-H、-C3-20cycloalkyl-OC (O) -C1-40Alkyl- [ O-C1-40alkyl-C (O)]p-(O-C1-40Alkyl radical)q-O-C1-40Alkyl, -C3-20cycloalkyl-OC (O) -C1-40Alkyl- [ O-C1-40alkyl-C (O)]p-(O-C1-40Alkyl radical)q-OH、-C1-40alkyl-OC (O) -C1-40Alkyl- [ O-C1-40alkyl-C (O)]p-(O-C1-40Alkyl radical)q-O-C1-40Alkyl, -C1-40alkyl-OC (O) -C1-40Alkyl- [ O-C1-40alkyl-C (O)]p-(O-C1-40Alkyl radical)q-OH、-C3-20cycloalkyl-O- (C)1-40alkyl-O)r-C1-40Alkyl, -C3-20cycloalkyl-O- (C)1-40alkyl-O)r-H、-(C1-40alkyl-O)r-C1-40Alkyl, - (C)1-40alkyl-O)r-H、-C3-20cycloalkyl-C1-40Alkyl, -hydroxy or C1-40An alkyl hydroxy-substituted 3-20 membered heterocyclic group; wherein the subscripts of the repeating units, such as p, q, r, are the same or different from each other and are independently selected from a number of from 1 to 500, such as a number of from 1 to 200, for example an integer of from 1 to 200;
according to an embodiment of the invention, R4Is selected from C1-20Alkyl radical, C2-20Alkenyl radical, C3-20Cycloalkyl radical, C3-20Cycloalkenyl, 3-20 membered heterocyclyl, -C1-20alkyl-OC (O) -PEG, -C1-20alkyl-OC (O) -PEG-C1-20Alkyl, -C1-20alkyl-OC (O) -C1-20alkyl-C (O) -PDLLA-PEG, -C1-20alkyl-OC (O) -C1-20alkyl-C (O) -PDLLA-PEG-C1-20Alkyl, -C1-20alkyl-OC (O) -C1-20alkyl-C (O) - (O-C)1-20alkyl-CO)p-(O-C1-20Alkyl radical)q-C1-20Alkyl, -C1-20alkyl-OC (O) -C1-20alkyl-C (O) - (O-C)1-20alkyl-CO)p-(O-C1-20Alkyl radical)q-H、-C1-20alkyl-OCO2-(C1-20alkyl-O)r-C1-20Alkyl, -C1-20alkyl-OCO2-(C1-20alkyl-O)r-H、-C3-20cycloalkyl-OC (O) -C1-20Alkyl- [ O-C1-20alkyl-C (O)]p-(O-C120Alkyl radical)q-O-C1-20Alkyl, -C3-20cycloalkyl-OC (O) -C1-20Alkyl- [ O-C1-20alkyl-C (O)]p-(O-C1-20Alkyl radical)q-OH、-C1-20alkyl-OC (O) -C1-20Alkyl- [ O-C1-20alkyl-C (O)]p-(O-C1-20Alkyl radical)q-O-C1-20Alkyl, -C1-20alkyl-OC (O) -C1-20Alkyl- [ O-C1-20alkyl-C (O)]p-(O-C1-20Alkyl radical)q-OH、-C3-20cycloalkyl-O- (C)1-20alkyl-O)r-C1-20Alkyl, -C3-20cycloalkyl-O- (C)1-20alkyl-O)r-H、-(C1-20alkyl-O)r-C1-40Alkyl, - (C)1-20alkyl-O)r-H、-C3-20cycloalkyl-C1-20Alkyl, -hydroxy or C1-20An alkyl hydroxy-substituted 3-20 membered heterocyclic group; (ii) a Wherein p, q, r are the same or different and are independently selected from the group consisting of a number from 1 to 500, such as a number from 1 to 200, for example an integer from 1 to 200;
or, -O-R4Selected from ethylene glycol, ethylene glycol monoalkyl ethers (e.g. polyethylene glycol mono C)1-40Alkyl ethers), polyethylene glycol (PEG) or polyethylene glycol monoalkyl ethers (e.g. polyethylene glycol mono C)1-40Alkyl ether) to remove a hydrogen atom from a hydroxyl group at the end of polyethylene glycol;
according to an embodiment of the invention, the PDLLA may optionally be bonded to other groups by removing a hydrogen atom from one of the hydroxyl groups.
According to embodiments of the invention, the PEG may be bonded to other groups, optionally by removal of a hydrogen atom from one or both of the hydroxyl groups.
The R isa、Rb、RcIdentical or different, independently of one another, from the group consisting of F, Cl, Br, I, OH, SH, CN, N3、=O、C1-20Alkyl radical, C2-20Alkenyl radical, C3-20A cycloalkyl group.
According to an embodiment of the invention, the molecular weight of the PEG and the PDLLA are the same or different and are independently selected from 100 to 5000, e.g. 150 to 3000, such as 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1100, 1200, 1300, 1400, 1500, 1600, 1700, 1800, 1900, 2000, 2100, 2200, 2300, 2400, 2500, 2600, 2700, 2800, 2900, 3000.
According to an embodiment of the invention, said R1Is selected from-CH3、-Ph、-CH2Br、-CH2I、-CH2N3、-C6H13Or
According to an embodiment of the invention, said R2Is selected from a substituent obtained by removing a hydrogen atom on one hydroxyl group of polyethylene glycol, or a substituent obtained by removing a hydrogen atom on one hydroxyl group of polyethylene glycol monoalkyl ether, or is selected from the following groups:
The invention also provides a preparation method of the compound shown in the formula (I), racemate, stereoisomer, tautomer or pharmaceutically acceptable salt thereof, which comprises the following steps of reacting the compound shown in the formula D-H with the compound shown in the formula (I-1) to obtain the compound shown in the formula (I):
wherein, D, R1、R2、R3Independently of one another have the definitions stated above;
Rhh selected from CH and D-H capable of being linked thereto combines to form R3Or R ishIs selected from R3Removal of the group CH2The resulting radical.
For example, RhCan be selected from H, RcOr optionally substituted by one, two or more RcSubstituted C1-39An alkyl group; as an example, when R3When selected from methyl, RhIs H. Preferably, RhIs inert in the reaction.
According to an embodiment of the invention, the reaction may be carried out in an inert atmosphere, for example in a nitrogen atmosphere.
According to an embodiment of the invention, the reaction may be carried out in the presence of a catalyst, for example in the presence of a protic acid such as at least one of p-toluenesulfonic acid, pyridine p-toluenesulfonic acid, 1, 2-dichloroacetic acid.
According to the embodiment of the present invention, when the drug D-H contains a plurality of hydroxyl groups, the OH group at the reaction site may be protected by a conventional method and then reacted with the compound represented by formula (I-1); and after the reaction is finished, removing the protecting group by adopting a conventional method to obtain the compound shown in the formula (I).
According to an embodiment of the invention, the reaction further comprises the preparation of a compound of formula (I-1), comprising at least one of the following processes:
the method comprises the following steps: in nonpolar solvent, ketal compounds are prepared from triflate siloxanyl compounds (TMSOTf, etc.) and organic base (such as Et)3N, DIPEA, etc.) to yield:
The second method comprises the following steps: when R ishWhen it is H, in a non-polar solvent, compound R1C(O)OR4Reaction with Tebbe reagent gives:
The third method comprises the following steps: the ketal compound is heated to eliminate one molecule of alcohol under the catalysis of acid (p-toluenesulfonic acid and the like) to obtain:
wherein R is1、R4、RhAre independent of each otherThe ground has the definition as described above.
According to an embodiment of the present invention, the non-polar solvent may be selected from, for example, one, two or more of halogenated hydrocarbons, ethers, aromatic hydrocarbon solvents, such as Dichloromethane (DCM), Tetrahydrofuran (THF), toluene.
The present invention also provides a compound represented by the formula (I-1):
wherein R is1、R2、RhIndependently of one another have the definitions stated above;
the invention also provides a pharmaceutical composition, which comprises a therapeutically effective amount of the compound shown in the formula (I), and racemate, stereoisomer, tautomer or pharmaceutically acceptable salt thereof.
According to an embodiment of the present invention, the pharmaceutical composition may optionally further comprise pharmaceutically acceptable excipients, such as carriers, excipients. By way of example, the adjuvants may be selected from one or more of the following: disintegrants, glidants, lubricants, diluents or fillers, binders, colorants.
According to an embodiment of the present invention, the pharmaceutical composition may be a pharmaceutical formulation, which may be selected from dosage forms including, but not limited to, injection solutions, nanoparticles, micelle formulations, and the like.
The invention also provides application of the compound shown in the formula (I), racemate, stereoisomer, tautomer or pharmaceutically acceptable salt thereof in preparing medicaments.
According to an embodiment of the present invention, the drug has the same use as the above-described drug compound containing at least one hydroxyl group, for example, it may be a taxane, a glucocorticoid, a prostaglandin analog, paliperidone, an artemisinin analog, a nucleoside analog, an antibiotic, an antiviral drug, naltrexone, rotigotine, rapamycin, tacrolimus, treprostinil, amsufamine, etoposide, halofugine, combretastatin, SN-38, rapamycin, fulvestrant, abiraterone, a statin, an analgesic, an IDO inhibitor NLG919, or a terpenoid.
The invention also provides a compound shown in the formula (I), a racemate, a stereoisomer, a tautomer or pharmaceutically acceptable salts thereof, or the use of said pharmaceutical composition in the prevention or treatment of a disease or condition which can be treated by a pharmaceutical compound containing at least one hydroxyl group as described above, such as those that may be alleviated or alleviated by administration of a taxane, glucocorticoid, prostaglandin analog, paliperidone, artemisinin analog, nucleoside analog, antibiotic, antiviral drug, naltrexone, rotigotine, rapamycin, tacrolimus, treprostinil, amsufamine, etoposide, halofuginone, combretastatin, SN-38, rapamycin, fulvestrant, abiraterone, statin, analgesic, IDO inhibitor NLG919 or terpenoid.
The invention also provides a compound shown in the formula (I), a racemate, a stereoisomer, a tautomer or a pharmaceutically acceptable salt thereof, or an application of the pharmaceutical composition in improving the physical property, the chemical property or the pharmaceutical property of the pharmaceutical compound containing at least one hydroxyl.
The invention also provides a compound shown in the formula (I), a racemate, a stereoisomer, a tautomer or a pharmaceutically acceptable salt thereof, or an application of the pharmaceutical composition in improving the metabolism or release characteristics of the pharmaceutical compound containing at least one hydroxyl.
The invention also provides a compound shown in the formula (I), a racemate, a stereoisomer, a tautomer or a pharmaceutically acceptable salt thereof, or an application of the pharmaceutical composition in improving the solubility of the pharmaceutical compound containing at least one hydroxyl in water or an organic solvent.
The invention also provides a compound shown in the formula (I), a racemate, a stereoisomer, a tautomer or a pharmaceutically acceptable salt thereof, or an application of the pharmaceutical composition in improving the drug effect or side effect of the pharmaceutical compound containing at least one hydroxyl.
Advantageous effects
1) The prodrug of the invention can obviously improve the physical and chemical properties of the original initial drug, such as solving the problem of poor solubility of the original initial drug such as taxane drugs in water. The hydrophilic ketal improves the solubility of the medicinal compound in water, improves the anti-tumor effect of the medicament in vivo, and even can reduce the toxic and side effects caused by certain auxiliary materials (such as auxiliary materials in taxane injections) of the original initial medicinal preparation; in addition, the fat-soluble ketal prodrug makes the variety of abundant pharmaceutical preparations possible, and the pharmacological action (such as in vivo antitumor effect) of the ketal prodrug is obviously superior to that of the commercial preparation.
2) The prodrug of the invention can improve the solubility of the original initial drug in an organic solvent, for example, facilitates the preparation of a glucocorticosteroid nano preparation and improves the in-vivo treatment effect.
3) The fat-soluble prodrugs of the present invention can reduce the solubility of the original starting drug in aqueous solution, thereby being useful for achieving a long-lasting sustained release against chronic disease-treating drugs (such as glucocorticoids, prostaglandin analogs, paliperidone, dihydroartemisinin, nucleoside analogs, antiviral drugs, etc., as exemplified herein).
Definition and description of terms
Unless otherwise indicated, the definitions of radicals and terms described in the specification and claims of the present application, including definitions thereof as examples, preferred definitions, definitions of specific compounds in the examples, and the like, may be arbitrarily combined and coupled with each other. The definitions of the groups and the structures of the compounds in such combinations and after the combination are within the scope of the present specification.
Where a range of numerical values is recited in the specification and claims herein, and where the range of numerical values is defined as an "integer," it is understood that the two endpoints of the range are recited and each integer within the range is recited. For example, "an integer of 0 to 10" should be understood to describe each integer of 0,1, 2,3,4, 5,6, 7, 8, 9, and 10. An integer of "0 to 200" is to be understood as each integer describing 0,1, 2,3,4, 5,6, 7, 8, 9,10, 11, … …,100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, … …, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200.
When a range of values is defined as "a number," it is understood that the two endpoints of the range, each integer within the range, and each decimal within the range are recited.
The term "halogen" refers to F, Cl, Br and I. In other words, F, Cl, Br, and I may be described as "halogen" in the present specification.
The term "C1-40Alkyl is understood to mean a straight-chain or branched, saturated monovalent hydrocarbon radical having from 1 to 40 carbon atoms, preferably C1-20Alkyl, further preferably C1-10An alkyl group. "C1-10Alkyl "is understood to preferably mean a straight-chain or branched, saturated monovalent hydrocarbon radical having 1,2, 3,4, 5,6, 7, 8, 9 or 10 carbon atoms. The alkyl group is, for example, a methyl group, an ethyl group, a propyl group, a butyl group, a pentyl group, a hexyl group, an isopropyl group, an isobutyl group, a sec-butyl group, a tert-butyl group, an isopentyl group, a 2-methylbutyl group, a 1-ethylpropyl group, a 1, 2-dimethylpropyl group, a neopentyl group, a 1, 1-dimethylpropyl group, a 4-methylpentyl group, a 3-methylpentyl group, a 2-ethylbutyl group, a 1-ethylbutyl group, a 3, 3-dimethylbutyl group, a2, 2-dimethylbutyl group, a 1, 1-dimethylbutyl group, a2, 3-dimethylbutyl group, a 1, 3-dimethylbutyl group or a 1, 2-dimethylbutyl group. In particular, the radicals have 1,2, 3,4, 5,6 carbon atoms ("C)1-6Alkyl groups) such as methyl, ethyl, propyl, butyl, isopropyl, isobutyl, sec-butyl, tert-butyl, more particularly groups having 1,2 or 3 carbon atoms ("C)1-3Alkyl groups) such as methyl, ethyl, n-propyl or isopropyl.
The term "C2-40Alkenyl "is understood to preferably mean a straight-chain or branched monovalent hydrocarbon radical comprising one or more double bonds and having from 2 to 40 carbon atoms, preferably" C2-20Alkenyl ", alsoPreferably "C2-10Alkenyl ". "C2-10Alkenyl "is understood to preferably mean a straight-chain or branched, monovalent hydrocarbon radical which contains one or more double bonds and has 2,3,4, 5,6, 7, 8, 9 or 10 carbon atoms, in particular 2 or 3 carbon atoms (" C2-3Alkenyl "), it being understood that in the case where the alkenyl group comprises more than one double bond, the double bonds may be separated from each other or conjugated. The alkenyl group is, for example, vinyl, allyl, (E) -2-methylvinyl, (Z) -2-methylvinyl, (E) -but-2-enyl, (Z) -but-2-enyl, (E) -but-1-enyl, (Z) -but-1-enyl, pent-4-enyl, (E) -pent-3-enyl, (Z) -pent-3-enyl, (E) -pent-2-enyl, (Z) -pent-2-enyl, (E) -pent-1-enyl, (Z) -pent-1-enyl, hex-5-enyl, (E) -hex-4-enyl, (Z) -hex-4-enyl, m-n-2-enyl, m-n-1-enyl, m-n-E-4-enyl, m-n-2-, (E) -hex-3-enyl, (Z) -hex-3-enyl, (E) -hex-2-enyl, (Z) -hex-2-enyl, (E) -hex-1-enyl, (Z) -hex-1-enyl, isopropenyl, 2-methylprop-2-enyl, 1-methylprop-2-enyl, 2-methylprop-1-enyl, (E) -1-methylprop-1-enyl, (Z) -1-methylprop-1-enyl, 3-methylbut-3-enyl, 2-methylbut-3-enyl, 1-methylbut-3-enyl, 3-methylbut-2-enyl, (E) -2-methylbut-2-enyl, (Z) -2-methylbut-2-enyl, (E) -1-methylbut-2-enyl, (Z) -1-methylbut-2-enyl, (E) -3-methylbut-1-enyl, (Z) -3-methylbut-1-enyl, (E) -2-methylbut-1-enyl, (Z) -2-methylbut-1-enyl, (E) -1-methylbut-1-enyl, (Z) -1-methylbut-1-enyl, 1-dimethylprop-2-enyl, 1-ethylprop-1-enyl, 1-propylvinyl group and 1-isopropylvinyl group.
The term "C2-40Alkynyl "is understood to mean a straight-chain or branched monovalent hydrocarbon radical comprising one or more triple bonds and having from 2 to 40 carbon atoms, preferably" C2-C20Alkynyl ", also preferred is" C2-C10Alkynyl ". The term "C2-C10Alkynyl "is understood as preferably meaning a straight-chain or branched, monovalent hydrocarbon radical which contains one or more triple bonds and has 2,3,4, 5,6, 7, 8, 9 or 10 carbon atoms, in particular 2 or 3 carbon atoms (" C2-C3-alkynyl "). Said alkynyl is, for example, ethynyl, prop-1-ynyl, prop-2-ynylBut-1-alkynyl, but-2-alkynyl, but-3-alkynyl, pent-1-alkynyl, pent-2-alkynyl, pent-3-alkynyl, pent-4-alkynyl, hex-1-alkynyl, hex-2-alkynyl, hex-3-alkynyl, hex-4-alkynyl, hex-5-alkynyl, 1-methylpropan-2-alkynyl, 2-methylbut-3-alkynyl, 1-methylbut-2-alkynyl, 3-methylbut-1-alkynyl, 1-ethylprop-2-alkynyl, 3-methylpent-4-alkynyl, 2-methylpent-4-alkynyl, di-n-3-alkynyl, di-n-2-alkynyl, di-n-3-methylbut, 1-methylpent-4-ynyl, 2-methylpent-3-ynyl, 1-methylpent-3-ynyl, 4-methylpent-2-ynyl, 1-methylpent-2-ynyl, 4-methylpent-1-ynyl, 3-methylpent-1-ynyl, 2-ethylbut-3-ynyl, 1-ethylbut-2-ynyl, 1-propylprop-2-ynyl, 1-isopropylprop-2-ynyl, 2-dimethylbut-3-ynyl, 1-dimethylbut-2-ynyl or 3, 3-dimethylbut-1-ynyl. In particular, the alkynyl group is ethynyl, prop-1-ynyl or prop-2-ynyl.
The term "C3-20Cycloalkyl is understood to mean a saturated monovalent monocyclic or bicyclic hydrocarbon ring having 3 to 20 carbon atoms, preferably "C3-10Cycloalkyl groups ". The term "C3-10Cycloalkyl "is understood to mean a saturated monovalent monocyclic or bicyclic hydrocarbon ring having 3,4, 5,6, 7, 8, 9 or 10 carbon atoms. Said C is3-10Cycloalkyl groups may be monocyclic hydrocarbon groups such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl or cyclodecyl, or bicyclic hydrocarbon groups such as decalin rings.
The term "3-20 membered heterocyclyl" means a saturated monovalent monocyclic or bicyclic hydrocarbon ring comprising 1-5 heteroatoms independently selected from N, O and S, preferably "3-10 membered heterocyclyl". The term "3-10 membered heterocyclyl" means a saturated monovalent monocyclic or bicyclic hydrocarbon ring comprising 1-5, preferably 1-3 heteroatoms selected from N, O and S. The heterocyclic group may be attached to the rest of the molecule through any of the carbon atoms or nitrogen atom (if present). In particular, the heterocyclic group may include, but is not limited to: 4-membered rings such as azetidinyl, oxetanyl; 5-membered rings such as tetrahydrofuranyl, dioxolyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, pyrrolinyl; or a 6-membered ring such as tetrahydropyranyl, piperidinyl, morpholinyl, dithianyl, thiomorpholinyl, piperazinyl, or trithianyl; or a 7-membered ring such as diazepanyl. Optionally, the heterocyclic group may be benzo-fused. The heterocyclyl group may be bicyclic, for example but not limited to a5, 5 membered ring, such as a hexahydrocyclopenta [ c ] pyrrol-2 (1H) -yl ring, or a5, 6 membered bicyclic ring, such as a hexahydropyrrolo [1,2-a ] pyrazin-2 (1H) -yl ring. The nitrogen atom containing ring may be partially unsaturated, i.e., it may contain one or more double bonds, such as, but not limited to, 2, 5-dihydro-1H-pyrrolyl, 4H- [1,3,4] thiadiazinyl, 4, 5-dihydrooxazolyl, or 4H- [1,4] thiazinyl, or it may be benzo-fused, such as, but not limited to, dihydroisoquinolinyl. According to the invention, the heterocyclic radical is non-aromatic.
The term "C6-20Aryl "is understood to preferably mean a mono-, bi-or tricyclic hydrocarbon ring having a monovalent or partially aromatic character with 6 to 20 carbon atoms, preferably" C6-14Aryl ". The term "C6-14Aryl "is to be understood as preferably meaning a mono-, bi-or tricyclic hydrocarbon ring having a monovalent or partially aromatic character with 6, 7, 8, 9,10, 11, 12, 13 or 14 carbon atoms (" C6-14Aryl group "), in particular a ring having 6 carbon atoms (" C6Aryl "), such as phenyl; or biphenyl, or is a ring having 9 carbon atoms ("C9Aryl), such as indanyl or indenyl, or a ring having 10 carbon atoms ("C10Aryl radicals), such as tetralinyl, dihydronaphthyl or naphthyl, or rings having 13 carbon atoms ("C13Aryl radicals), such as the fluorenyl radical, or a ring having 14 carbon atoms ("C)14Aryl), such as anthracenyl.
The term "5-20 membered heteroaryl" is understood to include such monovalent monocyclic, bicyclic or tricyclic aromatic ring systems: having 5 to 20 ring atoms and comprising 1 to 5 heteroatoms independently selected from N, O and S, such as "5-14 membered heteroaryl". The term "5-14 membered heteroaryl" is understood to include such monovalent monocyclic, bicyclic or tricyclic aromatic ring systems: which has 5,6, 7, 8, 9,10, 11, 12, 13 or 14 ring atoms, in particular 5 or 6 or 9 or 10 carbon atoms, and which comprises 1 to 5, preferably 1 to 3, heteroatoms each independently selected from N, O and S and, in addition, can be benzo-fused in each case. In particular, heteroaryl is selected from thienyl, furyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, triazolyl, thiadiazolyl, thia-4H-pyrazolyl and the like and their benzo derivatives, such as benzofuryl, benzothienyl, benzoxazolyl, benzisoxazolyl, benzimidazolyl, benzotriazolyl, indazolyl, indolyl, isoindolyl and the like; or pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, and the like, and benzo derivatives thereof, such as quinolyl, quinazolinyl, isoquinolyl, and the like; or azocinyl, indolizinyl, purinyl and the like and benzo derivatives thereof; or cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, naphthyridinyl, pteridinyl, carbazolyl, acridinyl, phenazinyl, phenothiazinyl, phenoxazinyl, and the like.
Unless otherwise indicated, heterocyclyl, heteroaryl or heteroarylene include all possible isomeric forms thereof, e.g., positional isomers thereof. Thus, for some illustrative, non-limiting examples, pyridyl or pyridinylene includes pyridin-2-yl, pyridinylene-2-yl, pyridin-3-yl, pyridinylene-3-yl, pyridin-4-yl, and pyridinylene-4-yl; thienyl or thienylene includes thien-2-yl, thien-3-yl and thien-3-yl.
The above for the term "alkyl", e.g. "C1-40The definition of alkyl "applies equally to compounds containing" C1-40Other terms for alkyl radicals, e.g. the term "C1-40Alkoxy "and the like.
The term "inert atmosphere" according to the present invention shall be understood as an atmosphere inert to the reaction, including, but not limited to, one, two or more atmospheres selected from helium (He), neon (Ne), argon (Ar), krypton (Kr), xenon (Xe), nitrogen.
Drawings
FIG. 1 shows Oleyl-K-7-PTX/DSPE-PEG2000Characterization of nanoparticles: transmission electron microscopy (left panel) and dynamic light scattering (right panel).
FIG. 2 shows mPEG2000The treatment effect of the-K-7-PTX injection and the self-made commercial Genex xol paclitaxel micelle preparation on the tumor of an A2780 tumor-bearing mouse (left panel) and the weight change graph of a nude mouse (right panel). The time points indicated by the arrows are injection time points.
FIG. 3 shows Oleyl-K-7-PTX/DSPE-PEG2000The effect of nanoparticles and self-made commercial taxol on the tumor inhibition of MDA-MB-231 tumor-bearing mice is shown in the figure. Dosage: 20mg/kg paclitaxel; the time points indicated by the arrows are injection time points.
FIG. 4 is a graph showing the inhibitory effect of mPEG-PDLLA-K-2' -PTX micelles and the commercially available Genex paclitaxel micelle preparation on MDA-MB-231 tumor-bearing mice tumors. Dosage: 10mg/kg paclitaxel; the time points indicated by the arrows are injection time points.
FIG. 5 shows mPEG1000The effect of-K-Cab injection and the home-made commercial cabazitaxel preparation on the inhibition of MDA-MB-231 tumor-bearing mice tumors is shown. mPEG1000-K-Cab dose: 10mg/kg cabazitaxel; dose of the self-made commercial cabazitaxel formulation: 3mg/kg cabazitaxel; the time points indicated by the arrows are injection time points.
FIG. 6 shows SA-K-DEX/DSPE-PEG2000Characterization of nanoparticles: transmission electron microscopy (left panel) and dynamic light scattering (right panel).
FIG. 7 shows the tail vein injection of SA-K-DEX/DSPE-PEG2000The effect of the nanoparticles on treating arthritis of rats is shown in the figure. Dosage: 1.0mg/kg dexamethasone; the time points indicated by the arrows are injection time points.
Fig. 8 is a MicroCT image of the joint after the rat arthritis treatment experiment was completed.
FIG. 9 is the distribution of dexamethasone in the rat joints 4 hours after tail vein injection. Dosage: corresponding to 1.0mg/kg dexamethasone.
FIG. 10 is an optical microscope photograph of SA-K-DEX nanocrystals.
FIG. 11 is a graph showing the therapeutic effect of SA-K-DEX nanocrystals injected into the joints of rats on arthritis. Dosage: equivalent to 2.5mg/kg dexamethasone; the time points indicated by the arrows are injection time points.
FIG. 12 is a test of dexamethasone concentration in blood after intra-articular injection of SA-K-DEX nanocrystals in rats. Dosage: corresponding to 2.5mg/kg dexamethasone.
FIG. 13 shows SA-K-TAF/DSPE-PEG2000Characterization of nanoparticles: transmission electron microscopy (left panel) and dynamic light scattering (right panel).
FIG. 14 is a graph showing changes in intra-ocular pressure of New Zealand rabbits. Dosage: equivalent to 10 mug/body of tafluprost; the time points indicated by the arrows are injection time points.
FIG. 15 shows intramuscular injection of Oleyl-K-PAL/DSPE-PEG to rats2000The concentration of paliperidone in blood after nanoparticles was tested. Dosage: equivalent to paliperidone 20 mg/kg; the time points indicated by the arrows are injection time points.
FIG. 16 shows the intramuscular injection of SA-K-DHA/DSPE-PEG to rats2000And (4) testing the concentration of dihydroartemisinin in blood after nanoparticles are generated. Dosage: equivalent to 20mg/kg of dihydroartemisinin; the time points indicated by the arrows are injection time points.
FIG. 17 shows the results of the SA-K-5' -GEM cytotoxicity assay.
FIG. 18 shows rat intramuscular injection of SA-K-5' -AZT/DSPE-PEG2000Concentration of zidovudine in blood after nanoparticles was tested. Dosage: equivalent to 20mg/kg of zidovudine; the time points indicated by the arrows are injection time points.
FIG. 19 shows rat blood injection of mPEG2000Measurement of the concentration of testosterone in the blood after K-TES. Dosage: equivalent to testosterone 1 mg/kg; the time points indicated by the arrows are injection time points.
FIG. 20 shows the therapeutic effect of β -glucose-K-etoposide injection and Toposar, a commercially available etoposide preparation, on A549 tumor-bearing mice. The time points indicated by the arrows are injection time points. The dose is 15mg/kg etoposide.
Detailed Description
The technical solution of the present invention will be further described in detail with reference to specific embodiments. It is to be understood that the following examples are only illustrative and explanatory of the present invention and should not be construed as limiting the scope of the present invention. All the technologies realized based on the above-mentioned contents of the present invention are covered in the protection scope of the present invention.
Unless otherwise indicated, the raw materials and reagents used in the following examples are all commercially available products or can be prepared by known methods.
Liquid chromatograph: agilent 1260Infinity II, Agilent technologies, Inc.; nuclear magnetism: switzerland brueck, AV 400; a multifunctional microplate reader: bio Tek, Synergy 4.
The control groups referred to in the following examples in comparison with the activity of the commercial preparations mean, unless otherwise specified, the groups to which no drug was administered.
The experimental animal source is as follows: nude mice: beijing Wittiulihua laboratory animal technology Co., Ltd, balb/c-Nude, 6-8 weeks, female, 20 g; adult SD rats: beijing Wittiulihua laboratory animal technology Co., Ltd, 9-11 weeks, female, 200-; 2.5-3kg of New Zealand rabbits. Experimental rats were housed in an SPF-scale experimental environment, while rabbits were housed in a common clean environment.
EXAMPLE 1 Synthesis of hexanol isopropenyl ether
Reference is made to The literature methods (Killian, D.B., G.F.Hennion, and J.A.Nieuwland. "The Preparation of The Some α -unreacted Ethers from 2, 2-dimethyl-akutanes 1." Journal of The American Chemical Society 57.3(1935): 544-545.).
120g of 2, 2-methoxyoctane and 0.05g of p-toluenesulfonic acid were placed in a 250mL round-bottom flask and heated to reflux. After refluxing reaction for 4h, reduced pressure distillation is carried out to obtain the product hexanol isopropenyl ether.1H NMR (400MHz, benzene-d)6):δ3.90(dd,J=7.9,1.3Hz,2H),3.52(t,J=6.5Hz,2H),1.81(s,3H),1.55(dt,J=14.7,6.6Hz,2H),1.32–1.10(m,6H),0.84(t,J=7.0Hz,3H)。
EXAMPLE 2 Synthesis of (1-methoxyvinyl) benzene
Reference is made to the literature (Pine S H, Zahler R, Evans D A, et al titanium-functionalized ethylene-transfer reactions direct conversion of esters inter vinyl ethers [ J ] Journal of the American Chemical Society,1980,102(9): 3270) 3272).
1mmol of methyl phenylacetate was dissolved in 2ml of a mixed solvent of toluene and tetrahydrofuran (3:1), the system was cooled to-40 ℃ and then a toluene solution (0.55M) of 1.1mmol of Tebbe reagent was slowly added dropwise thereto, the reaction was continued at this temperature for 30min, then warmed to room temperature and continued for 1.5h,after the reaction is completed, the system is cooled to-10 ℃, 1ml of 15% sodium hydroxide aqueous solution is added to the system for quenching, then the system is warmed to room temperature, ether extraction is carried out, anhydrous sodium sulfate is dried, filtration and concentration are carried out, and a colorless liquid product is obtained after silica gel column chromatography separation and purification.1H NMR (400MHz, benzene-d)6):δ7.73–7.67(m,2H),7.17–7.05(m,3H),4.65(d,J=2.7Hz,1H),4.05(d,J=2.7Hz,1H),3.31(s,3H)。
Example 3 Synthesis of Cholesterol isopropenyl Ether
Reference is made to the literature (Dujardin, G., Rossgnol, S., & Brown, E. (1995). effective Current polymerization-free preparation of vinyl and isopentene ethers of basic secondary alcohols and. alpha. -hydroxyers. tetrahedron leaves, 36(10), 1653-. The specific method comprises the following steps:
adding 10mmol of cholesterol, 25mL of dichloromethane and 60mmol of 2-methoxypropene into a reaction bottle, adding 0.05mmol of p-toluenesulfonic acid (p-TSA) as a catalyst under the protection of nitrogen, adding 0.5mL of triethylamine after the reaction is completely monitored by a dot plate to terminate the reaction, removing the solvent, and carrying out silica gel column chromatography to obtain the ketal protected cholesterol.
Adding 1mmol of ketal-protected cholesterol, 5mL of tetrahydrofuran and 1.3mmol of DIPEA into a reaction bottle, cooling to-20 ℃, slowly dropwise adding 1mmol of trimethylsilyl trifluoromethanesulfonate into the reaction bottle, returning to room temperature, and stirring for reaction overnight. After the reaction was completed, 3mL of 1M aqueous sodium hydroxide solution was added thereto, liquid separation was performed, the aqueous phase was extracted with dichloromethane, the organic phases were combined, washed with water, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, concentrated, and separated by silica gel column chromatography to obtain a colorless liquid product.1H NMR (400MHz, benzene-d)6):δ5.33–5.39(m,1H,CH,=CH),3.93–4.05(m,3H,CH,=CH2),2.68(m,1H,CH),2.40–2.50(m,1H,CH),2.00–2.09(m,2H,CH2),1.93(m,1H,CH),1.86(s,3H,CH3),1.50–1.73(m,6H,3CH2),1.36–1.46(m,6H,3CH2),0.98–1.31(m,14H,CH3,4CH2,3CH),0.92–0.95(m,9H,3CH3),0.67(s,3H,CH3).13C NMR(100MHz,C6D6):δ157.87,140.38,121.87,81.61,75.67,56.72,56.24,50.21,42.28,39.87,39.60,38.46,37.16,36.78,36.35,35.87,32.01,31.87,28.28,28.06,27.95,24.26,24.02,22.67,22.42,21.50,21.06,19.14,18.71,11.73.HRMS(ESI):m/z calcd for C30H50O[M+Na]+:449.3754;found 449.3759。
EXAMPLE 4 Synthesis of beta-2, 3,4, 6-tetrabenzyl-D-glucopyranose isopropenyl ether
Beta-1-chloro-2, 3,4, 6-tetrabenzyl-D-glucopyranose (24.3mmol), bisacetylmethylmercury and chloroform are added into a 500mL two-neck flask and reacted under reflux. The expected product is obtained in the form of a yellow solid, 8.9g, yield 70.5%.1H NMR(CDCl3):δ7.38–7.25(m,17H),7.18(dd,J=6.9,2.6Hz,3H),4.96(d,J=10.9Hz,2H),4.90–4.73(m,5H),4.65–4.50(m,4H),4.27(d,J=1.9Hz,1H),4.13(s,1H),3.81–3.51(m,4H),1.92(s,3H).
Example 5: hexanol-2 '-paclitaxel acetonide conjugate (HE-K-2' -PTX)
Paclitaxel (0.1mmol, 1eq), dichloromethane 1.5mL, hexanol isopropenyl ether (0.6mmol) were added to The reaction flask under nitrogen (Killian, D.B., G.F. Hennion, and J.A. Nieuwland. "The Preparation of The sodium α -unreacted Ethers from 2, 2-dimethyl yalkanes1." The Journal of The American Chemical Society 57.3(1935):544 and 545.), followed by The addition of The catalyst dichloroacetic acid (0.05 eq). After TLC monitoring raw material paclitaxel reaction is complete, adding 200. mu.L triethylamine to stop reaction, concentrating, and separating by silica gel column chromatography to obtain white solid product HE-K-2' -PTX with yield of 80.3%.1H NMR (400MHz, acetonitrile-d)3):δ8.1–8.1(m,2H),7.8–7.8(m,2H),7.7–7.7(m,1H),7.6–7.5(m,4H),7.5(dd,J=7.9,1.7Hz,4H),7.4(t,J=7.7Hz,2H),7.3–7.2(m,1H),6.3(s,1H),6.1–6.0(m,1H),5.6(d,J=7.2Hz,1H),5.5(dd,J=8.3,6.1Hz,1H),4.9(dd,J=9.7,2.2Hz,1H),4.6(d,J=6.2Hz,1H),4.3(dd,J=11.0,6.6Hz,1H),4.1(s,2H),3.7(d,J=7.1Hz,1H),3.4–3.3(m,1H),3.0(dt,J=8.9,6.7Hz,1H),2.8(s,1H),2.5–2.4(m,1H),2.4(s,3H),2.1(s,3H),2.1–2.0(m,1H),1.9(d,J=1.5Hz,3H),1.8–1.7(m,1H),1.7–1.7(m,1H),1.6(s,3H),1.3(s,4H),1.3(s,3H),1.3–1.2(m,10H),1.1(s,3H),1.1(s,3H),0.9(t,J=7.1Hz,3H).
Example 6: synthesis of Oleyl-7-taxol acetonide conjugate (Oleyl-K-7-PTX)
Wherein Oleyl represents Oleyl.
PTX-2' -TBS (0.1mmol, 1eq), dichloromethane (1.5 mL), Oleyl isopropenyl ether (0.6mmol) (Oleyl isopropenyl ether reference line S H, Zahler R, Evans D A, et al titanium-functionalized ethylene-transfer reactions, direct conversion of esters in vinyl ethers [ J ] Journal of the American Chemical Society,1980,102(9): 3272) was added under nitrogen protection, followed by dichloroacetic acid (0.05eq), and 200. mu.L of triethylamine was added thereto after TLC monitoring the completion of the reaction of the starting material PTX-2' -TBS, to terminate the reaction, and the resulting white solid product Oleyl-K-7-PTX-2' -TBS was directly charged to the next step.
Under the protection of nitrogen, crude Oleyl-K-7-PTX-2' -TBS (0.1mmol) in the previous step and 0.5mL of tetrahydrofuran are added into a tetrafluoroethylene reaction bottle, TBAF (0.15mmol) is added into the tetrafluoroethylene reaction bottle, the mixture is stirred at room temperature overnight, 5mL of saturated sodium bicarbonate aqueous solution is added into the tetrafluoroethylene reaction bottle after the raw materials are completely reacted, liquid separation is carried out, aqueous phase is extracted by DCM (3X 5mL), organic phase is combined, water washing is carried out, saturated salt water washing is carried out, anhydrous sodium sulfate is dried, filtering is carried out, concentration is carried out, silica gel column chromatography separation is carried out, and white solid product Oleyl-K-7-PTX is obtained, wherein.1H NMR (400MHz, chloroform-d): δ 8.15-8.07 (m,2H), 7.79-7.72 (m,2H), 7.65-7.57 (m,1H), 7.54-7.45 (m,5H), 7.43-7.30 (m,5H), 7.19-7.12 (m,1H),6.40(s,1H), 6.21-6.12 (m,1H),5.78(dd, J ═ 8.9,2.7Hz,1H),5.66(d, J ═ 6.9Hz,1H), 5.41-5.28 (m,2H),4.90(dd, J ═ 9.9,2.1Hz,1H),4.77(d, J ═ 2.7Hz,1H),4.39(dd, J ═ 6, J ═ 6.9, 2.1H), 4.7H, 3.3H, 3.7H, 3.3H, 3.7H, 3H, 4H) 1.74(s,3H),1.50(s,3H),1.40(m,2H), 1.35-1.14 (m,33H),0.87(t, J ═ 6.8Hz,3H).
Example 7: polyethylene glycol monomethyl ether2000-7-Taxol acetonide conjugate (mPEG)2000Synthesis of (E) -K-7-PTX)
To a reaction flask were added PTX-2' -TBS (0.1mmol, 1eq), dichloromethane 1.5mL, polyethylene glycol monomethyl ether (molecular weight 2000g/mol) isopropenyl ether (0.6mmol) (polyethylene glycol monomethyl ether isopropenyl ether references Pine S H, Zahler R, Evans D A, et al titanium-functionalized ethylene-transfer reactions, direct conversion of esters inter vinyl ethers [ J]The method described in Journal of the American Chemical Society,1980,102(9):3270-3272), followed by addition of dichloroacetic acid (0.05eq) as a catalyst, termination of the reaction by TLC monitoring the completion of the reaction of the starting PTX-2' -TBS with 200. mu.L of triethylamine, concentration and mPEG as a white solid product2000the-K-7-PTX-2' -TBS was directly subjected to the next step.
Adding the crude mPEG of the previous step into a tetrafluoro reaction bottle under the protection of nitrogen2000-K-7-PTX-2' -TBS (0.1mmol), tetrahydrofuran 5mL, adding TBAF (0.15mmol), stirring at room temperature overnight, after the raw materials completely react, adding 5mL saturated sodium bicarbonate aqueous solution, separating, extracting aqueous phase with DCM (3X 5mL), combining organic phases, washing with water, washing with saturated salt water, drying with anhydrous sodium sulfate, filtering, concentrating, and separating by silica gel column chromatography to obtain white solid product mPEG2000-K-7-PTX, two-step yield 53%.1H NMR (400MHz, B)Nitrile-d3):δ8.15–8.07(m,2H),7.94–7.89(m,2H),7.71–7.63(m,1H),7.57(t,J=7.6Hz,2H),7.54–7.47(m,3H),7.47–7.37(m,4H),7.31–7.24(m,1H),6.35(s,1H),6.14–6.01(m,1H),5.61(dd,J=8.5,4.8Hz,1H),5.56(d,J=7.1Hz,1H),4.91(dd,J=9.9,2.1Hz,1H),4.74(d,J=4.9Hz,1H),4.41(dd,J=10.8,6.4Hz,1H),4.18–4.07(m,2H),3.81–3.69(m,3H),3.55(s,220H),3.37(dd,J=5.8,3.7Hz,1H),3.29(s,3H),2.59–2.47(m,1H),2.37(s,3H),2.26(dt,J=15.4,7.9Hz,2H),2.12(s,3H),2.02(dd,J=13.5,7.7Hz,2H),1.88(d,J=1.4Hz,3H),1.66(s,3H),1.45(s,3H),1.16(s,3H),1.12(s,6H).
Example 8: synthesis of methanol-2 '-paclitaxel acetophenone conjugate (Ph-K-2' -PTX)
Paclitaxel (0.1mmol, 1eq), dichloromethane 1.5mL, 1-methoxyvinylbenzene (0.6mmol) (1-methoxyvinylbenzene reference: Tebbe, f.n., Parshall, g.w.,&reddy, G.D. (1978), Olefine homology with titanium methyl compounds, journal of the American chemical society,100(11), 3611-3613). To this was then added the catalyst dichloroacetic acid (0.005 mmol). After TLC monitoring raw material paclitaxel reaction is complete, adding 200. mu.l triethylamine to stop reaction, concentrating, and separating by silica gel column chromatography to obtain white solid product Ph-K-2' -PTX with yield of 70%.1H NMR (400MHz, acetonitrile-d)3):δ8.14–8.05(m,2H),7.88–7.80(m,2H),7.69–7.62(m,1H),7.55(td,J=7.1,4.4Hz,4H),7.47(t,J=7.6Hz,2H),7.38(d,J=5.1Hz,4H),7.24(ddd,J=20.8,8.0,5.6Hz,4H),7.12(d,J=7.2Hz,2H),6.33(s,1H),6.03(t,J=9.1Hz,1H),5.61–5.51(m,2H),4.92(dd,J=9.7,2.2Hz,1H),4.32(dd,J=11.0,6.6Hz,1H),4.22(d,J=4.4Hz,1H),4.12(s,2H),3.71(d,J=7.1Hz,1H),3.07(s,3H),2.80(s,2H),2.44–2.35(m,1H),2.23–2.16(m,1H),2.14(s,3H),2.00(s,3H),1.82(dd,J=15.5,9.0Hz,1H),1.71(m,1H),1.58(d,J=1.7Hz,6H),1.13(s,3H),1.08(s,3H).
Example 9: synthesis of hexanol-2 '-docetaxel acetonide (HE-K-2' -DOC) conjugate
Docetaxel (0.1mmol, 1eq), dichloromethane (1.5 mL), hexanol isopropenyl ether (0.6mmol) were added to a reaction flask under nitrogen (hexanol isopropenyl ether reference Killian, D.B., G.F.Hennion, and J.A. Nieuwland. "The Preparation of The sodium α -unreacted Ethers from 2, 2-dimethyl yalkanes1." Journal of The American Chemical Society 57.3(1935): 544-) 545) followed by The addition of The catalyst dichloroacetic acid (0.05 eq). After TLC monitoring material docetaxel reaction is completed, adding 200. mu.L triethylamine to terminate the reaction, concentrating, and separating by silica gel column chromatography to obtain white solid product HE-K-2' -DOC with yield of 64%.1H NMR (400MHz, acetonitrile-d)3):δ8.16–8.10(m,2H),7.73–7.67(m,1H),7.61(t,J=7.5Hz,2H),7.39(d,J=6.5Hz,4H),7.27(td,J=6.4,3.0Hz,1H),6.06(t,J=9.1Hz,2H),5.56(d,J=7.0Hz,1H),5.08(s,1H),5.01(dd,J=9.8,2.0Hz,1H),4.81(s,1H),4.45(d,J=5.0Hz,1H),4.22–4.10(m,2H),3.87(dd,J=10.6,6.5Hz,1H),3.78(d,J=6.9Hz,1H),3.37(s,3H),3.26(s,3H),2.87–2.66(m,3H),2.43(s,3H),2.15(d,J=26.6Hz,1H),1.68–1.58(m,4H),1.38(s,9H),1.34–1.15(m,15H),1.13(s,3H),1.10(s,3H),0.91(t,J=7.1Hz,3H).
Example 10: polyethylene glycol monomethyl ether1000-Cabazitaxel acetonide conjugate (mPEG)1000Synthesis of-K-Cab)
Cabazitaxel (0.1mmol, 1eq), dichloromethane (1.5 mL), TES mono-protected hexanediol isopropenyl ether (0.6mmol) (TES mono-protected hexanediol isopropenyl ether reference Tebbe, f.n., Parshall, g.w., & Reddy, g.d. (1978) made by the method of Olefin polymerization with titanium methyl ether compounds. journal of the American chemical society,100(11), 3611-3613) were added to a reaction flask under nitrogen, followed by the catalyst dichloroacetic acid (0.05 eq). After TLC monitoring the reaction of the raw material cabazitaxel is completed, 200 mu L of triethylamine is added to the mixture to terminate the reaction, the mixture is concentrated, and the obtained white solid is directly put into the next step.
Adding the crude product (0.1mmol) of the previous step and 5mL of tetrahydrofuran into a 15mL tetrafluoroethylene reaction bottle under the protection of nitrogen, adding TBAF (0.15mmol), stirring overnight at room temperature, adding 5mL of saturated sodium bicarbonate aqueous solution after the raw materials react completely, separating, extracting the aqueous phase with DCM (3X 5mL), combining the organic phases, washing with water, washing with saturated salt water, drying with anhydrous sodium sulfate, filtering, concentrating, and separating by silica gel column chromatography to obtain a white solid product C6diol-K-2' -Cab, two-step yield 63%.
Adding the product C in the last step into a reaction bottle under the protection of nitrogen6diol-K-2' -Cab (0.1mmol), dichloromethane (5.0 mL), triethylamine (0.6mmol), polyethylene glycol monomethyl ether (molecular weight 1000g/mol) p-nitrophenyl carbonate (0.11mmol) are added, TLC monitors that the raw materials react completely, then the raw materials are directly concentrated, and the product mPEG is obtained after silica gel column chromatography1000-K-Cab, yield 75%.1H NMR (400MHz, acetonitrile-d)3):δ8.16–8.10(m,2H),7.75–7.68(m,1H),7.62(dd,J=8.3,6.8Hz,2H),7.45–7.35(m,4H),7.30–7.24(m,1H),6.10–5.98(m,2H),5.55(d,J=7.0Hz,1H),5.15–5.06(m,1H),5.02(dd,J=9.8,2.0Hz,1H),4.81(s,1H),4.45(d,J=4.9Hz,1H),4.26–4.06(m,7H),3.87(dd,J=10.7,6.5Hz,1H),3.81–3.72(m,2H),3.70–3.44(m,105H),3.37(s,3H),3.32(s,3H),3.27(s,3H),3.21(s,1H),2.94(q,J=7.3Hz,2H),2.81–2.65(m,3H),2.44(s,3H),2.19(d,J=11.2Hz,1H),1.95(s,5H),1.63(d,J=5.1Hz,6H),1.39(s,9H),1.36–1.16(m,17H),1.13(s,3H),1.09(s,3H).
Example 11: synthesis of polyethylene glycol monomethyl ether-polylactic acid-2 '-paclitaxel acetonide conjugate (mPEG-PDLLA-K-2' -PTX)
Paclitaxel (1mmol, 1eq) and TES monoprotected hexanediol isopropenyl ether (6mmol) were charged into a 100mL Schlenk flask, the nitrogen gas was replaced, methylene chloride (25mL) was added and the mixture was dissolved with stirring, and dichloroacetic acid (0.05eq) was added. Triethylamine is added into a system after the raw materials completely react, then the mixture is subjected to desolventizing and column chromatography to obtain a compound PTX-K-C6-OTES, a white solid is obtained, and the yield is as follows: 36 percent.
PTX-K-C6-OTES (0.36mmol) was added to a 10mL Schlenk tube, THF (2mL) was added and dissolved with stirring, followed by TBAF tetrahydrofuran solution (0.40 mmol). After the reaction is finished, adding a saturated sodium bicarbonate diluting system, dissolving ethyl acetate, extracting with water and saturated sodium chloride, drying with anhydrous sodium sulfate, removing the solvent from the filtrate, and performing column chromatography to obtain white solid PTX-K-C6-OH with the yield of 71%.
To a 25mL Schlenk tube was added mPEG with a carboxylic acid end group2000-PDLLA1750(0.12mmol), DMAP (0.012mmol), EDC (0.16mmol) and dichloromethane (4mL) were dissolved with stirring and pyridine (0.6mL) was added. After activating the system for 20min, the PTX-K-C6-OH (0.144mmol) prepared in the previous step is added into the system, and the reaction is carried out at 25 ℃. After the reaction is finished, adding dichloromethane to dilute the system, washing twice with a small amount of water and a saturated NaCl solution in sequence, then drying with anhydrous sodium sulfate, desolventizing, and carrying out column chromatography to obtain a compound mPEG-PDLLA-K-2' -PTX, wherein the white solid is obtained in yield: 75 percent.1H NMR (400MHz, chloroform-d): δ 8.12(d, J ═ 7.6Hz,2H),7.76(d, J ═ 7.8Hz,2H),7.61(s,1H),7.56 to 7.39(m,11H),7.19(d, J ═ 8.1Hz,1H),6.28(s,1H),6.24(t, J ═ 8.1,1H),5.67(d, J ═ 7.1Hz,1H),5.59(dd, J ═ 8.1,3.7Hz,1H),5.18 to 5.09(m,24H),4.97(d, J ═ 9.7Hz,1H),4.67(d, J ═ 3.6Hz,1H),4.36 to 4.16(m,9H),4.05(t, J ═ 6, 3.7H, 1H),4.36 to 4.16(m,9H),4.05(t, J ═ 6, 3.7, 3.68H), 3.67 (m,1H), 3.23.6H, 1H), 3.23, 1H, 3.23.6H, 1H, 3.6H, 1H, 3.6H, 1.
The taxane ketal derivatives of tables 1-3 were prepared from the above drugs by the methods of reference examples 5-11.
Example 12: hydrolysis rate test of taxane ketal prodrug conjugates
mu.L of the prodrug to be tested (prodrug prepared in the above example) in acetonitrile (7.5mM) was added to 3mL of hydrolysis buffer (pH 5.0, 50mM, containing 40% V acetonitrile) at 37.0 ℃. Rapidly taking 100 mu L of hydrolysis sample at 1min,3min,5min,15min,0.5h,1h,2h,4h,8h,12h,24h and 48h, adding 100 mu L of hydrolysis termination buffer solution (pH 8.0, 200mM containing 40% V acetonitrile) to terminate hydrolysis, uniformly mixing, measuring the contents of hydrolysis raw materials and hydrolysis products by liquid chromatography, fitting a hydrolysis curve, calculating the hydrolysis half-life period, and testing for 4 times in parallel. The test results are shown in tables 1-3.
As can be seen from tables 1 to 3, the taxane ketal prodrug conjugate has a very obvious acid sensitivity property, and the half-life period is as short as 3mins at the shortest and 29838mins at the longest under the condition of pH 5.0, so that the purpose of controlling the acid sensitivity degree of the taxane drugs can be achieved through molecular design.
The hydrolysis activity of different reaction sites of the paclitaxel is different, and the reaction activity of the 7 site of the paclitaxel is obviously better than that of the 2' site. Meanwhile, the hydrolytic activity and the structure of the same reaction site are closely related, and the following rules are found: when the substituent on the ketal is a cyclic structure, the hydrolytic activity of the ketal is superior to that of a chain structure; the carbon atom connected with the ketal is a secondary carbon atom, and the reactivity is better than that of a primary carbon; the hydrolytic activity of the electron withdrawing group is reduced.
Example 13: cytotoxicity testing of taxane conjugate prodrugs
Cell culture conditions: DMEM high-sugar medium, 10% FBS, 1% P/S, 37 ℃, 5% CO2。
MDA-MB-231 cells were seeded into 96-well plates at 3000/well density the day before the experiment. On the day of the experiment, the prodrug prepared in the above example was dissolved in DMSO, the drug was diluted to various concentrations with the medium, and added to a 96-well plate (n ═ 4). After the cells were incubated with the pro-drugs prepared in the above examples for an additional 3 days in the incubator, the medium was changed to 100. mu.L of fresh medium + 10. mu.L of CCK-8 solution. After further incubation for 2h, OD 450nm was measured and IC calculated according to CCK-8 instructions50. The test results are shown in tables 1-3.
It can be seen from tables 1-3 that the pro-drugs prepared by the present invention have a killing effect on cancer cells close to that of paclitaxel. Meanwhile, the cytotoxicity data are identical with the results of in vitro hydrolysis experiments, which shows that the prodrug constructed by utilizing the acid-sensitive ketal bond has high utilization value.
Example 14: preparation of hydrophilic taxane ketal conjugate prodrug injection
For water soluble ketal prodrugs mPEG2000-K-7-PTX and mPEG1000-K-Cab, the water-soluble prodrugs were dissolved directly in 10mM PB buffer (pH 7.4), respectively. After the dissolution, the mixture was filtered through a 0.45 μm sterile filter to obtain an injection, and the concentration of the drug was measured by HPLC.
Example 15: preparation of lipophilic taxane ketal couple prodrug nanoparticles
Taking Oleyl-K-7-PTX as an example: accurately weighing 7mg of Oleyl-K-7-PTX and 3mg of DSPE-mPEG2000Dissolving the two in 350 mu L of absolute ethyl alcohol, slowly dripping the ethanol solution into a PBS (pH 8.0) buffer solution (6.7mM) under stirring, stabilizing for 5min, removing the ethanol by using a rotary evaporator to obtain prodrug nanoparticles, filtering by using a 0.45 mu m sterile filter membrane, measuring the concentration of the prodrug in the nanoparticles by using HPLC, and performing DLS and TEM tests on the prepared prodrug nanoparticles. The detection result is shown in FIG. 1, and it can be seen from FIG. 1 that DLS data and TEM data are consistent, and Oleyl-K-7-PTX/DSPE-PEG prepared by the invention2000The particle size of the nanoparticles is about 100nm, which is beneficial to the enrichment of the nano-drugs on tumor parts through EPR effect.
Example 16: preparation of amphiphilic taxane ketal conjugate prodrug micelle
Using mPEG-PDLLA-K-2' -PTX as an example, 5mg of amphiphilic taxane ketal prodrug was dissolved in 500. mu.L of acetone and added dropwise slowly with stirring to a 25mL round-bottomed flask containing 5.0mL of pH 7.4PB buffer (10 mM). Prodrug micelles were prepared by rotary evaporation at room temperature for 15min to remove acetone, ultracentrifugation (10K MWCO) to concentrate mPEG-PDLLA-K-2' -PTX micelles to 0.5 mL. HPLC was used to calculate the drug concentration in the micelles.
Example 17: in vivo antitumor evaluation of taxane conjugate prodrug preparation
Female balb/c-nu nude mice with age of 4-6 weeks and weight of 16-20g are purchased from Beijing Witonglihua laboratory animal technology Limited and bred in SPF-level laboratory animal houses.
The right armpit of the nude mouse is implanted with 5 multiplied by 10 under the skin6A2780 or MDA-MB-231 cells. The tumor volume is about 100mm3At the same time, tumor-bearing mice were randomly grouped (7-10 mice per group). The preparation for the treatment control group was prepared in the laboratory according to the formulation of the commercially available paclitaxel. After intravenous injection, the tumor growth size and the weight of each group of nude mice are recorded, and a tumor growth curve chart and a weight change rate chart are drawn. Tumor volume calculation formula: vtumor=(length×width2)/2。
When the tumor volume of A2780 is up to 2000mm3MDA-MB-231 tumor volume up to 1000mm3At that time, the nude mice were sacrificed.
mPEG2000The test results of the-K-7-PTX injection are shown in FIG. 2, and mPEG can be obtained from FIG. 22000the-K-7-PTX injection has good safety and drug effect, the administration dosage can be improved to more than 3 times of the highest tolerance dosage of the commercial drug, the injection has good anti-tumor activity, the side effect (such as weight reduction degree) is obviously reduced, and the effect of the injection is better than that of the commercial drug paclitaxel micelle.
Oleyl-K-7-PTX/DSPE-PEG2000The results of the testing of the nanoparticles and the home-made commercially available taxol are shown in fig. 3. As can be seen from FIG. 3, the nano-preparation prepared by the invention has good anti-tumor activity under the dosage of 20mg/kg paclitaxel, and the effect is better than that of the commercial drug (20mg/kg paclitaxel). In addition, compared with taxol in use, the preparation of the invention only needs to be diluted by PBS and does not need to be dissolved by castor oil and ethanol, so that the preparation is safer and easier to administer.
The results of the testing of mPEG-PDLLA-K-2' -PTX micelles and the home-made commercial paclitaxel micelle Genexol formulation (dose 10mg/kg based on paclitaxel) are shown in FIG. 4. As can be seen from FIG. 4, the mPEG-PDLLA-K-2' -PTX micelle prepared by the invention has obviously better anti-tumor activity than that of the conventional medicine under the condition of the same dosage (10mg/kg of paclitaxel).
mPEG1000The results of the tests on the injection of-K-Cab and the injection of cabazitaxel on the market are shown in FIG. 5, and it can be seen from FIG. 5 that mPEG prepared by the present invention is measured at the maximum tolerance of mice1000The in vivo anti-tumor activity of the-K-Cab injection (10mg/kg cabazitaxel) is obviously better than that of the commercial cabazitaxel injection (3mg/kg cabazitaxel). At the same time, mPEG can be realized1000The high-dose administration of the-K-Cab injection is obviously better than that of the Cabazitaxel injection on the market in safety.
Example 18: synthesis of stearyl alcohol-dexamethasone acetonide conjugate (SA-K-DEX)
Dexamethasone (1mmol) and stearyl isopropenyl ether (6mmol, 1eq) (stearyl isopropenyl ether reference: Pine S H, Zahler R, Evans D A, et al titanium-modified methyl-transfer reactions, direct conversion of esters inter vinyl ethers [ J]Journal of the American Chemical Society,1980,102(9):3270-3272) was placed in a Schlenk bottle, and the gas in the replacement system was nitrogen. 5mL of tetrahydrofuran was added to dissolve the resulting solution, and then dichloroacetic acid (0.2eq) was added to react at 25 ℃. The reaction was followed by TLC, and after completion of the reaction, 100. mu.L of triethylamine was added to quench the reaction. The solvent was spin dried and purified on silica gel column to give white powder with a yield of 92%.1H NMR (400MHz, chloroform-d): δ 7.18(d, J ═ 10.1Hz,1H),6.33(d, J ═ 10.1Hz,1H),6.11(s,1H),4.45(d, J ═ 17.8Hz,1H),4.38(d, J ═ 10.0Hz,1H),4.20(d, J ═ 17.8Hz,1H),3.39(t, J ═ 7.0Hz,2H), 3.11-3.01 (m,1H),2.90(s,1H),2.61(m,1H),2.37(m,3H), 2.26-2.16 (m,1H), 1.87-1.68 (m,2H),1.54(s,3H), 1.51-1.47 (m,3H),1.43(s,1H), 1.86 (s,1H),6.93 (s,6H), 6.07 (s,1H), 1H, 6.07 (s, 3H).
The glucocorticoid ketal derivatives of table 4 were prepared starting from the above drugs by the method of reference example 18.
Example 19: hydrolysis rate test of dexamethasone ketal couple prodrug
The dexamethasone ketal conjugate prodrug is dissolved in 600 μ L acetonitrile and mixed with 12.5mL of pH 5.0 digest (containing 0.1% Tween 80) to a final dexamethasone ketal conjugate prodrug concentration of about 50 μ M. Shaking table incubation at 37.0 deg.C for hydrolysis of prodrug (100rpm), caching 100 μ L of sample in 3min,6min,9min,15min,25min,30min,45min,1h,1.5h,2h,3h,6h, adding 100 μ L of phosphate buffer (200mM) pH 8.0, mixing, and placing in a refrigerator at 4 deg.C. Finally, the hydrolysis half-life and solubility were determined by HPLC, and the results of the measurements are shown in Table 4.
As can be seen from table 4, by replacing different R side chains, the dexamethasone acetonide prodrug exhibited different physicochemical properties, such as exhibiting different solubility and hydrolysis half-lives. Increasing the carbon chain length of the aliphatic side chain can significantly increase the solubility of the prodrug in methylene chloride. The different types of side chains also have an effect on the hydrolysis rate of the prodrug, generally speaking, secondary aliphatic alcohol side chains hydrolyze faster than primary aliphatic alcohol side chains, and PEG side chains hydrolyze faster than primary aliphatic alcohol side chains. Therefore, the hydrolysis speed and the solubility of the dexamethasone acetonide prodrug prepared by the invention in an organic solvent are obviously improved, so that the preparation of a nano preparation is more convenient, and the in-vivo treatment effect is improved.
Example 20: SA-K-DEX/DSPE-PEG2000Preparation of nanoparticles
6mg of SA-K-DEX and 4mg of DSPE-PEG2000Dissolving in 1mL of absolute ethanol, and performing ultrasonic treatment until the solution is clear. This ethanol solution was slowly dropped into 10mL of a pH 8.0PBS buffer (6.7mM) while stirring. Stirring at room temperature until ethanol is completely volatilized, and filtering with 0.45 μm filter membrane to obtain SA-K-DEX/DSPE-PEG2000And (3) carrying out ultracentrifugation on the nanoparticle solution until the concentration of SA-K-DEX in the solution is 1 mg/mL. The solution can be stored in a refrigerator at 4 deg.C, and diluted to a specific concentration with PBS (6.7mM) pH 8.0 according to the requirement of intravenous injection. The transmission electron microscopy image (left image) and the dynamic light scattering image (right image) of the nanoparticles are shown in FIG. 6.
As shown in FIG. 6, SA-K-DEX/DSPE-PEG2000The nanoparticles are typically spherical, the particle size distribution of the nanoparticles is narrow, and the average particle size is about 58 nm.
Example 21: in-vivo efficacy evaluation of SA-K-DEX/DSPE-PEG nanoparticles
Establishment of a CIA rat model: 180-200g male SD rats were bred for one week and acclimatized. Mixing 2mg/mL cattle type II collagen and incomplete adjuvant in equal volume, emulsifying completely, and preparing into emulsion with collagen final concentration of 1 mg/mL. For the initial immunization, 200. mu.L of the emulsion was injected into the tail group of rats, and 100. mu.L of the emulsion was injected into the tail group after 7 days. The foot of the rat started to red and swollen 10 days after the primary immunization. The experiment set up model group (dexamethasone phosphate injection), normal control group, medication group (SA-K-DEX/DSPE-PEG nanoparticles), each group of 7 rats.
Nanoparticle dosing regimen: the administration was carried out on days 15, 20 and 25 after the primary immunization, the rats were sacrificed by injecting nanoparticle solution (1mg/kg) into the tail vein and ending the experiment on day 28, and the effect of the treatment was observed by MicroCT.
The therapeutic effect is shown in fig. 7 and 8. In the rat CIA model used in the experiment, the hindpaw of the rat started to become red and swollen at the 10 th day after the initial immunization, and the swelling peak is reached at the 15 th day. SA-K-DEX/DSPE-PEG was seen after three tail vein injections of the drug2000The nanoparticle group and the dexamethasone sodium phosphate injection group have treatment effects compared with the control group. The average plantar thickness of the SA-K-DEX/DSPE nanoparticle group at 28 days is 5.3cm, which is not different from that of normal rats, while the average plantar thickness of the dexamethasone sodium phosphate injection group is 6.2cm, which has swelling phenomenon and more obvious inflammation rebound tendency. It can be seen that the nano preparation of the invention improves the treatment effect on arthritis, and the main reason is that the nano particles can effectively enrich at the arthritis focus part through the isolation (ELVIS) function of permeable blood vessels and inflammatory cells mediated, and simultaneously release free dexamethasone through acidolysis. After the rats are sacrificed at 28 days, the results of the micct scanning of the ankle joints of the rats are shown in fig. 8, the bone surface near the inflamed joints is seriously damaged, the joint bone surface of the SA-K-DEX/DSPE nanoparticle group is smooth, and the bone density approaches to normal, which shows that the SA-K-DEX/DSPE nanoparticles prepared by the invention have better prevention and treatment effects on the arthritis bone damage.
Example 22: SA-K-DEX/DSPE-PEG nanoparticle joint distribution
The rats were sacrificed 4 hours after single injection of SA-K-DEX/DSPE-PEG nanoparticles and dexamethasone phosphate injection into the CIA rats, and the inflammatory joints were removed. Samples were processed according to the standard procedures for LC-MS testing, and the concentration of dexamethasone drug in the joint was determined by LC-MS. To determine the overall concentration of dexamethasone in the joint, the sample needs to be subjected to acidolysis to release dexamethasone.
The results of LC-MS data in the drug in vivo distribution experiment are shown in FIG. 9. As can be seen from FIG. 9, the overall content and the free content of dexamethasone are higher than those of dexamethasone sodium phosphate injection group at the inflamed ankle joint, and significant differences exist, which proves that the nanoparticles have an enrichment effect at the inflamed joint part and are the key point for improving the drug effect of SA-K-DEX.
Example 23: preparation of SA-K-DEX nanocrystals
A2 mL centrifuge tube was charged with 500mg of zirconia steel beads and 300. mu.L of SA-K-DEX absolute ethanol solution (containing 3mg of SA-K-DEX), followed by 600. mu.L of aqueous pH 9.0 NaOH. The centrifuge tube is opened and put into a refrigerator at 4 ℃ to volatilize ethanol for about 48 hours.
Adding 100 μ L of 2% Tween 80 aqueous solution into the rest solution, and stirring with vortex instrument (2700 rpm) for 0.5-6 h to obtain size-adjustable SA-K-DEX nanocrystal. The morphology and size of the nanocrystals can be roughly observed by optical microscopy.
The results of light microscope examination of the nanocrystals are shown in fig. 10. As can be seen from FIG. 10, under the optical microscope, the SA-K-DEX nanocrystals showed needle-like crystals with a length of 10-15 μm.
After stirring was complete, the well dispersed liquid was transferred to a centrifuge tube. After centrifugation, the supernatant was discarded. An appropriate amount of aqueous solution containing 0.1% tween 80 was added. Repeating the steps for 3 times, and freeze-drying the nanocrystalline for later use. Before use, resuspend with pH 7.4PBS and disperse well using vortex.
Example 24: in vivo efficacy evaluation of dexamethasone formulations
The model was made as in example 21, nanocrystal dosing schedule: rats were injected with SA-K-DEX nanocrystals (dose 2.5mg/kg SA-K-DEX) at the ankle cavity on day 21 after the initial immunization, and the experiment was sacrificed at the end of day 50.
The test results are shown in fig. 11. As can be seen in FIG. 11, the therapeutic effect was stable for at least 28 days after administration after the intra-articular injection of SA-K-DEX nanocrystals.
Example 25: determination of dexamethasone concentration in dexamethasone nanocrystalline blood
After 14, 21 and 28 days of injection of SA-K-DEX nanocrystals (dose in SA-K-DEX: 2.5mg/kg) in inflamed joints of rats, blood was taken. The samples were processed according to the standard procedures for LC-MS testing of blood samples, and the concentration of dexamethasone drug in the blood was determined by LC-MS. To determine the overall concentration of dexamethasone in the blood, the sample needs to be subjected to acidolysis to release dexamethasone.
The dexamethasone concentration in the rat plasma was measured periodically and the results of the LC-MS data are shown in fig. 12. As can be seen from FIG. 12, total dexamethasone with a concentration of more than 20ng/mL can be detected at days 14, 21 and 28, which indicates that SA-K-DEX nanocrystal can be slowly hydrolyzed and released in rat articular cavity, significantly prolongs the retention time of dexamethasone in rat body, and improves the treatment effect.
Example 26: synthesis of stearyl alcohol-tafluprost acetonide conjugate (SA-K-TAF)
TBS-TAF (0.1mmol, 1eq) and stearyl isopropenyl ether (0.6mmol) were placed in a Schlenk flask, and the atmosphere inside the replacement system was nitrogen. 2mL of tetrahydrofuran was added to dissolve the resulting solution, and dichloroacetic acid (0.2eq) was added to react at 25 ℃. The reaction was followed by TLC, and after completion of the reaction, 100. mu.L of triethylamine was added to quench the reaction. The solvent was spin-dried and purified on silica gel column to give a colorless oil.
This oil was dissolved in tetrahydrofuran, tetrabutylammonium fluoride (0.08mmol) was added, and the reaction was stirred at 25 ℃. After the reaction is completed, the solvent is dried by spinning, and then the mixture is purified by a silica gel column to obtain colorless oily substance SA-K-TAF, wherein the yield is 60%.1H NMR (400MHz, chloroform-d): δ 7.35-7.27 (m,2H), 7.03-6.96 (m,1H),6.91(d, J ═ 9.7Hz,2H),6.09(m,1H), 5.88-5.70 (m,1H), 5.45-5.28 (m,2H),5.08–4.94(m,1H),4.32–4.13(m,3H),3.89(s,1H),3.42(m,2H),2.46–2.38(m,1H),2.32–2.13(m,4H),2.12–1.99(m,3H),1.95–1.82(m,1H),1.67(d,J=7.6Hz,2H),1.56–1.46(m,2H),1.35(d,J=6.6Hz,6H),1.25(s,32H),1.22(d,J=6.3Hz,6H),0.88(t,J=6.8Hz,3H).
example 27: synthesis of Cholesterol-Tafluprost acetonide conjugate (Chol-K-TAF)
TBS-TAF (0.1mmol) and cholesterol isopropenyl ether (0.6mmol, 1eq) (cholesterol isopropenyl ether reference: Dujardin, G., Rosssignol, S.,&brown, E. (1995), effective current-free preparation of vinyl and isopropyl ethers of basic secondary alcohols and alpha-hydroxyers. tetrahedron letters,36(10), 1653) 1656) was placed in a Schlenk flask and the gas in the displacement system was nitrogen. 2mL of tetrahydrofuran was added to dissolve the resulting solution, and dichloroacetic acid (1.0eq) was added to react at 25 ℃. The reaction was followed by TLC, and after completion of the reaction, 100. mu.L of triethylamine was added to quench the reaction. The solvent was spin-dried and purified on silica gel column to give a colorless oil. This oil was dissolved in tetrahydrofuran, tetrabutylammonium fluoride (0.08mmol) was added, and the reaction was stirred at 25 ℃. After the reaction is completed, the solvent is dried by spinning, and then the product is purified by a silica gel column to obtain a colorless oily substance Chol-K-TAF, wherein the yield is 65 percent.1H NMR (400MHz, chloroform-d): δ 7.29(m,2H),6.99(t, J ═ 7.4Hz,1H),6.91(d, J ═ 8.8Hz,2H),6.09(m,1H),5.75(m,1H), 5.42-5.26 (m,3H),4.99(m,1H), 4.29-4.13 (m,3H),3.87(q, J ═ 5.2Hz,1H),3.51(m,1H), 2.45-2.39 (m,1H), 2.33-2.14 (m,6H), 2.08-1.92 (m,6H),1.81(d, J ═ 4.0Hz,4H), 1.76-1.69 (m,2H), 1.65-1.60 (m,2H),1.60 (m, 1.8H), 1.38(m, 1H), 1.9-1H, 1.8 (m,1H), 1.9-1.6H), 1.6H, 1.8 (m,1H), 1.6H, 1.
(d,J=6.3Hz,6H),1.19–1.04(m,8H),0.99(s,3H),0.91(d,J=6.5Hz,3H),0.86(m,6H),0.66(s,3H).
Ketal derivatives of prostaglandin analogs are prepared according to the methods of examples 26-27 starting with the above drugs.
Example 28: preparation of tafluprostone ketal prodrug nanoparticles
7mg of SA-K-TAF and 3mg of DSPE-PEG2000Dissolved in 1mL acetone and sonicated until the solution is clear. This acetone solution was slowly dropped into 10mL of pH 8.0PBS buffer (6.7mM) while stirring. Stirring at room temperature until acetone is completely volatilized, and filtering with 0.45 μm filter membrane to obtain SA-K-TAF/DSPE-PEG2000And (3) carrying out ultracentrifugation on the nanoparticle solution until the concentration of the prodrug in the solution is 1 mg/mL. The solution can be stored in a refrigerator at 4 ℃ and can be diluted to a specific concentration by using a PBS (6.7mM) buffer solution with the pH of 8.0 according to the requirement of intravenous injection amount when in use. As can be seen from FIG. 13, SA-K-TAF/DSPE-PEG was prepared2000The nano-particles are uniform and have the size of about 50 nanometers.
With reference to the above method, Chol-K-TAF nanoparticles were also prepared.
Example 29: effect of sub-conjunctival injection of Tafluprostone ketal prodrug nanoparticles on Normal Rabbit intraocular pressure
The experimental animals were New Zealand rabbits (body weight 3.5-4.5 kg) with normal intraocular pressure, and each group had 2 animals. Anaesthetizing New Zealand rabbit, dripping proparacaine hydrochloride eye drops into left eye, and mixing 100 μ L SA-K-TAF/DSPE-PEG with 27 # needle sterile injector2000The nanoparticle solution (equivalent to 10. mu.g of tafluprost after hydrolysis) was injected under the conjunctiva. Intraocular pressure was measured continuously with a small animal tonometer for one week at fixed times. Wherein animals as control group were not administered.
The test results are shown in fig. 14. As shown in FIG. 14, SA-K-TAF/DSPE-PEG2000The intraocular pressure of the rabbit can be effectively reduced within seven days after the nanoparticle subconjunctival injection, and the long-acting effect is expected to be realized.
Example 30: synthesis of Oleyl alcohol-paliperidone acetonide conjugate (Oleyl-K-PAL)
Adding paliperidone (0.1mmol, 1eq), dichloromethane (1.5 mL) and dichloroacetic acid (0.1mol) into a reaction flask under the protection of nitrogen, stirring at room temperature for 30min, adding Oleyl isopropenyl ether (0.6mmol), adding 400 uL triethylamine to the paliperidone after TLC monitoring the reaction of the raw material, stopping the reaction, concentrating, and separating by silica gel column chromatography to obtain a white solid product, namely Oleyl-K-7-PAL, with the yield of 83%.1H NMR (400MHz, chloroform-d): δ 7.66(dd, J ═ 8.7,5.1Hz,1H),7.18(dd, J ═ 8.5,2.1Hz,1H),6.99(td, J ═ 8.9,2.2Hz,1H),5.33 to 5.24(m,2H),4.72(t, J ═ 4.1Hz,1H),4.04(dt, J ═ 13.4,6.4Hz,1H),3.91(dt, J ═ 14.3,6.3Hz,1H),3.46(dt, J ═ 8.7,6.9Hz,1H),3.33(dt, J ═ 8.9,7.1Hz,1H),3.17 to 3.09(m,2H),3.08 to 2.97, 2.7, 1H, 3.7.7.7.1H, 1H, 3.17 to 3.09(m,2H), 3.7.7.7 (m-2H), 6.7, 6.7.7.7, 6.7.7H, 6.6.6H, 1H, 6H, 6.7H, 6.7.7H, 3H) in that respect
Example 31: Oleyl-K-PAL/DSPE-PEG2000Preparation of nanoparticles
Accurately weighing 7mg of Oleyl-K-PAL and 3mg of DSPE-mPEG2000Dissolving the two solutions in 350 μ L of anhydrous ethanol, slowly dropping the ethanol solution into PBS buffer (6.7mM) with pH 8.0 under stirring, stabilizing for 5min, removing ethanol with rotary evaporator, filtering with sterile filter membrane, and measuring drug concentration with HPLC.
Example 32: intramuscular injection of Oleyl-K-PAL/DSPE-PEG2000Determination of paliperidone concentration in blood after nanoparticles
Injection of Oleyl-K-PAL/DSPE-PEG in the hind leg muscle of rats2000Nanoparticles (dose: 20mg/kg) were bled at the indicated time points. The samples were processed according to the standard procedures for LC-MS testing of blood samples, and the concentration of paliperidone in the blood was determined by LC-MS.
The test results are shown in fig. 15. As shown in FIG. 15, Oleyl-K-PAL/DSPE-PEG2000The concentration of paliperidone in blood can be measured within 28 days after intramuscular injection of the nanoparticles, and the long-acting effect is expected to be realized.
Example 33: synthesis of stearyl alcohol-dihydroartemisinin acetonide conjugate (SA-K-DHA)
Dihydroartemisinin (0.3mmol, 1eq) and stearyl alcohol isopropenyl ether (1.8mmol) were placed in a Schlenk flask with nitrogen as the gas in the displacement system. After dissolving in 4mL of tetrahydrofuran, pyridine p-toluene sulfonic acid (PPTS) (0.05eq) was added and reacted at 25 ℃. The reaction was followed by TLC, and after completion of the reaction, 100. mu.L of triethylamine was added to quench the reaction. After the solvent is dried by spinning, the solvent is purified by a silica gel column to obtain white powder SA-K-DHA with the yield of 60 percent.1H NMR (400MHz, chloroform-d): δ 5.45(s,1H),5.23(d, J ═ 3.5Hz,1H),3.42(t, J ═ 7.0Hz,2H), 2.72-2.62 (m,1H),2.37(m,1H), 2.07-1.97 (m,1H), 1.90-1.77 (m,2H),1.76(d, J ═ 4.1Hz,1H),1.63(dd, J ═ 13.2,3.4Hz,1H), 1.57-1.45 (m,7H),1.41(s,3H),1.36(m,4H),1.26(s,32H),0.96(d, J ═ 6.3, 3H),0.88(dd, 7.1, 6.6, 6H).
Example 34: SA-K-DHA/DSPE-PEG2000Preparation of nanoparticles
Accurately weighing 7mg of SA-K-DHA and 3mg of DSPE-mPEG2000Dissolving the two solutions in 350 μ L of anhydrous ethanol, slowly dropping the ethanol solution into PBS buffer (6.7mM) with pH 8.0 under stirring, stabilizing for 5min, removing ethanol with rotary evaporator, filtering with sterile filter membrane, and measuring drug concentration with HPLC.
Example 35: intramuscular injection of SA-K-DHA/DSPE-PEG2000Determination of dihydroartemisinin concentration in blood after nanoparticles
Injection of SA-K-DHA/DSPE-PEG into the hind leg muscle of rats2000Nanoparticles (dose: 20mg/kg) were bled at the indicated time points. The samples were processed according to the standard procedures for LC-MS testing of blood samples, and the concentration of dihydroartemisinin in blood was determined by LC-MS.
The test results are shown in fig. 16. As shown in FIG. 16, SA-K-DHA/DSPE-PEG2000The concentration of dihydroartemisinin in blood can be measured within 28 days after the nanoparticle is injected into muscles, and long-acting effect is expected to be realized.
Example 36: synthesis of stearyl alcohol-5 '-gemcitabine acetonide conjugate (SA-K-5' -GEM)
0.44mmol of Fmoc-protected amino-gemcitabine (0.44mmol) was added to the reaction flask under nitrogen (Fmoc-protected amino-gemcitabine reference: Peter G.M.Wuts. (2014.) Greene's Protective Groups in Organic Synthesis, John Wiley&Sons, Inc. (prepared by the method of Fifth Edition), stearyl isopropenyl ether (1.32mmol), 4mL of tetrahydrofuran, and finally dichloroacetic acid (0.1eq) as a catalyst were added and reacted at 30 ℃. After TLC monitoring of the reaction, 10mL of dichloromethane and 0.2mL of DBU (1, 8-diazabicycloundecen-7-ene) were added. After the Fmoc deprotection in the TLC monitoring reaction was completed, 100mL of ethyl acetate was added for dilution, the mixture was washed with saturated sodium bicarbonate solution and saturated brine, and the organic phase was dried over anhydrous sodium sulfate, concentrated and separated by column chromatography to obtain a white waxy solid SA-K-5' -GEM with a yield of 77%.1H NMR (400MHz, chloroform-d): δ 7.81(d, J ═ 7.5Hz,1H),6.30(t, J ═ 7.1Hz,1H),5.85(d, J ═ 7.5Hz,1H),4.06(d, J ═ 8.4Hz,1H),3.82(d, J ═ 11.0Hz,1H),3.68(d, J ═ 11.5,3.3Hz,1H),3.37(t, J ═ 6.8Hz,2H), 1.57-1.44 (m,2H),1.37(s,6H), 1.32-1.21 (m,30H),0.87(t, J ═ 6.6Hz,3H).
Example 37: synthesis of stearyl alcohol-5 '-zidovudine acetonide conjugate (SA-K-5' -AZT)
0.75mmol (1eq) of zidovudine, stearyl alcohol isopropenyl ether (2.25mmol) and 5mL of tetrahydrofuran were added to a reaction flask under nitrogen protection, and finally dichloroacetic acid (0.1eq) was added to react at 30 ℃. After TLC monitoring reaction, 0.5mL triethylamine is added to stop reaction, and white waxy solid SA-K-5' -AZT is obtained after concentration and silica gel column chromatography separation, and the yield is 78%.1H NMR (400MHz, chloroform-d): δ 7.52(d, J ═ 1.3Hz,1H),6.23(t, J ═ 6.2Hz,1H), 4.27-4.19 (m,1H), 4.04-3.98 (m,1H),3.73(dd, J ═ 11.0,2.8Hz,1H),3.62(dd, J ═ 11.1,2.8Hz,1H), 3.45-3.32 (m,2H), 2.46-2.38 (m,1H), 2.34-2.25 (m,1H),1.91(d,J=1.2Hz,3H),1.62–1.48(m,2H),1.40(d,J=3.9Hz,6H),1.33–1.20(m,30H),0.86(t,3H)。
the acetonide prodrug was prepared according to the methods of examples 36-37 starting from the following drug molecules trifluridine, idoxuridine, floxuridine, capecitabine, lamivudine, emtricitabine, zalcitabine, cytarabine, ganciclovir, acyclovir, and doxorubicin, etc.
Example 38: cytotoxicity assays for gemcitabine conjugate prodrugs
Cell culture conditions: DMEM high-sugar medium, 10% FBS, 1% P/S, 37 ℃, 5% CO2。
A2780 or a549 cells were seeded into 96-well plates at 3000/well density the day before the experiment. On the day of the experiment, SA-K-5' -GEM was dissolved in DMSO, the drug was diluted to different concentrations with medium and added to 96-well plates (n ═ 4). After the cells were incubated with the pro-drugs prepared in the above examples for an additional 3 days in the incubator, the medium was changed to 100. mu.L of fresh medium + 10. mu.L of CCK-8 solution. After further incubation for 2h, OD 450nm was measured and IC calculated according to CCK-8 instructions50。
The test results are shown in fig. 17. As can be seen from FIG. 17, stearyl alcohol-5 '-gemcitabine acetonide conjugate (SA-K-5' -GEM) has stronger antitumor activity than gemcitabine.
Example 39: SA-K-5' -AZT/DSPE-PEG2000Preparation of nanoparticles
Accurately weighing 7mg of SA-K-5' -AZT and 3mg of DSPE-mPEG2000Dissolving the two solutions in 350 μ L of anhydrous ethanol, slowly dropping the ethanol solution into PBS buffer (6.7mM) with pH 8.0 under stirring, stabilizing for 5min, removing ethanol with rotary evaporator, filtering with sterile filter membrane, and measuring drug concentration with HPLC.
Example 40: intramuscular injection of SA-K-5' -AZT/DSPE-PEG2000Determination of zidovudine concentration in blood after nanoparticles
Injection of SA-K-5' in the hind leg muscle of ratsAZT/DSPE-PEG2000Nanoparticles (dose: 20mg/kg) were bled at the indicated time points. The samples were processed according to the standard procedures for LC-MS testing of blood samples, and the concentration of zidovudine in blood was determined by LC-MS. The test results are shown in fig. 18. As can be seen in FIG. 18, SA-K-DHA/DSPE-PEG2000The concentration of zidovudine in blood can be measured within 28 days after intramuscular injection of the nanoparticles, and the long-acting effect is expected to be realized.
Example 41: polyethylene glycol monomethyl ether-testosterone acetonide conjugate (mPEG)2000-K-TES) Synthesis
0.75mmol of polyethylene glycol monomethyl ether (molecular weight is 2000g/mol) isopropyl ether and 0.04mmol of p-toluenesulfonic acid are dissolved in 20mL of tetrahydrofuran, 0.1mmol of testosterone is added into the system, and the reaction is carried out at room temperature. After the reaction was complete, quench with 400. mu.L of TEA. The system was spun dry and purified to give 102mg of a white solid in 46% yield.1H NMR (400MHz, chloroform-d)3):δ5.72(s,1H),3.82(t,J=4.8Hz,1H),3.64(s,193H),3.49–3.44(m,1H),3.38(s,3H),2.47–2.23(m,4H),2.06–1.90(m,2H),1.84(d,J=15.8Hz,2H),1.73–1.35(m,7H),1.32(s,6H),1.19(s,3H),1.14–0.86(m,5H),0.79(s,3H)。
Ketal prodrugs of the testosterone, estradiol, ethinyl estradiol and lineestrol sex hormones listed above were prepared according to the method of example 41.
Example 42: intravenous injection mPEG of rat tail2000Determination of the concentration of testosterone in the blood after-K-TES
mPEG injection in tail vein of rat2000K-TES (dose: 1mg/kg) and blood was taken at the indicated time points. The samples were processed according to the standard procedures for LC-MS testing of blood samples, and the concentration of testosterone in the blood was determined by LC-MS.
The test results are shown in fig. 19. ByFIG. 19 shows that mPEG2000After intravenous injection, the-K-TES can be effectively converted into testosterone in blood, is a good water-soluble testosterone prodrug and can quickly take effect after injection.
Example 43: synthesis of beta-Glucose-K-etoposide acetonide conjugate (beta-Glucose-K-ETP)
To a 10mL Schlenk flask were added etoposide (0.1mmol), β -2,3,4, 6-tetrabenzyl-D-glucopyranose isopropenyl ether (0.6mmol), and dichloromethane (3 mL). After stirring well, a solution of dichloroacetic acid in dichloromethane (0.02mmol) was added to the system. The reaction was stirred at 30 ℃ for 5 hours. After the reaction was completed, triethylamine was added to quench the reaction. The system was desolventized and chromatographed on silica gel column to give the intermediate, white solid, 41 mg. After adding the intermediate (41mg,0.4mmol) to a 15mL hydrogenation tube and adding extra dry ethanol (1mL) and stirring well, 5% palladium hydroxide on carbon (100mg) was added to the system, with water previously removed with extra dry ethanol. Screwing down the hydrogenation reaction kettle, and filling 4 atmospheres to react for 96 hours. After the kettle is removed, the system is filtered to remove palladium carbon, the filtrate is desolventized, and a compound beta-Glucose-K-ETP is obtained by silica gel column chromatography, white solid is 26mg, yield: 90 percent.1H NMR(CDCl3):δ6.86(s,1H),6.51(s,1H),6.23(s,2H),5.96(s,2H),4.94(d,J=3.2Hz,1H),4.71–4.65(m,2H),4.58(d,J=5.3Hz,1H),4.53(d,J=7.6Hz,1H),4.46–4.39(m,1H),4.24–4.14(m,2H),3.84–3.77(m,3H),3.74(s,6H),3.55–3.44(m,5H),3.41–3.33(m,4H),3.23–3.13(m,2H),2.90–2.80(m,1H),1.50(d,J=2.8Hz,6H),1.33(d,J=4.9Hz,3H).
Example 44: in vivo antitumor evaluation of beta-glucose-K-etoposide prodrug
Female balb/c-nu nude mice with age of 4-6 weeks and weight of 16-20g are purchased from Beijing Witonglihua laboratory animal technology Limited and bred in SPF-level laboratory animal houses.
The right armpit of the nude mouse is implanted with 5 multiplied by 10 under the skin6And a549 cells. The tumor volume is about 100mm3In time, tumor-bearing mice were randomly grouped into groups. The formulation for the treatment control group was self-made in the laboratory according to the formulation of the commercially available formulation Toposar. After injection (dose: 15mg/kg etoposide), the tumor growth size and the weight of each group of nude mice are recorded, and a tumor growth curve chart and a weight change rate chart are drawn. Tumor volume calculation formula: vtumor=(length×width2)/2。
The test result of the beta-Glucose-K-ETP treatment is shown in figure 20, and as can be seen from figure 20, the beta-Glucose-K-ETP injection has good safety and drug effect, good anti-tumor activity and better effect than the commercial etoposide injection.
Example 45: synthesis of stearyl alcohol-NLG 919 acetonide conjugate (SA-K-NLG919)
1.0mmol of NLG919, stearyl isopropenyl ether (6.0mmol) and 20mL of dichloromethane were added to a reaction flask under nitrogen protection to dissolve, and dichloroacetic acid (0.7eq) was added to the mixture to react at 30 ℃ for 2 hours. After TLC monitoring reaction, 0.2mL triethylamine is added to stop reaction, and after concentration, silica gel column chromatography separation is carried out to obtain mucoid SA-K-NLG919 with the yield of 20%.1H NMR (400MHz, chloroform-d): δ 7.74(s,1H), 7.56-7.49 (m,1H),7.41(dd, J ═ 7.6,1.0Hz,1H),7.34(dd, J ═ 8.7,6.3Hz,1H),7.22(td, J ═ 7.5,1.2Hz,1H),7.17(d, J ═ 2.8Hz,1H),5.23(t, J ═ 5.9Hz,1H),3.92(td, J ═ 6.4,3.2Hz,1H), 3.49-3.31 (m,2H), 2.26-2.08 (m,3H), 1.88-1.51 (m,6H), 1.49-1.13 (m,42H), 0.90-0.84 (m,3H).
Example 46: synthesis of stearyl alcohol-Halofuginone acetonide conjugate (SA-K-Halofuginone)
Fmoc-protected amino-halofuginone (0.08mmol) (ref: Peter G.M.Wuts. (2014.) Greene's Protective Groups in Organic Synthesis, John Wiley&Sons, Inc (Fifth Edition)), stearyl alcohol isopropenyl ether(0.48mmol), 4mL of tetrahydrofuran was dissolved, and pyridinium p-toluenesulfonate (0.05eq) was added to react at 30 ℃ for 10 min. After completion of the TLC monitoring reaction, 10mL of dichloromethane and 0.08mL of DBU (1, 8-diazabicycloundecen-7-ene) were added, and after 5min at room temperature, 100mL of ethyl acetate was added for dilution, and the mixture was washed with saturated sodium bicarbonate solution and brine, and the organic phase was dried over anhydrous sodium sulfate. After concentration, white solid SA-K-Halofuginone is obtained by column chromatography separation, and the yield is 70 percent.1H NMR (400MHz, chloroform-d): δ 8.32(s,1H),8.04(s,1H),7.85(s,1H),4.80(q,2H), 3.53-3.33 (m,3H),3.09(dd, J ═ 16.1,4.0Hz,1H), 3.00-2.87 (m,2H),2.22(d, J ═ 12.1Hz,1H), 1.77-1.66 (m,1H), 1.59-1.45 (m,3H),1.36(d, J ═ 9.6Hz,6H), 1.33-1.20 (m,32H),0.88(t,3H).
Example 47: synthesis of stearyl alcohol-combretastatin acetonide conjugate (SA-K-CA4)
A15 ml Schlenk tube was taken, and 0.1mmol of the starting material combretastatin, 2.0ml of methylene chloride, and 0.6mmol of stearyl isopropenyl ether were added thereto, and 0.005mmol of 1, 2-dichloroacetic acid was added thereto with stirring. Reacting at room temperature, detecting by a dot plate, adding 300 mu l of triethylamine to terminate the reaction after the reaction is complete, directly carrying out spin drying, and carrying out silica gel column chromatography separation to obtain a white waxy product SA-K-CA4 with the yield of 73%.1H NMR (400MHz, chloroform-d): δ 7.16(s,1H),6.93(d, J ═ 8.4Hz,1H),6.74(d, J ═ 8.4Hz,1H),6.47(d, J ═ 7.4Hz,3H),6.39(d, J ═ 12.1Hz,1H),3.80(s,3H),3.78(s,3H),3.66(s,6H),3.54(t, J ═ 6.8Hz,2H),1.40(s,8H),1.25(d, J ═ 7.0Hz,37H),0.86(t, J ═ 6.7Hz,3H).
Example 48: synthesis of stearyl alcohol-7-ethyl-10-hydroxycamptothecin acetonide conjugate (SA-K-SN-38)
Taking a 15ml Schlenk tube, adding raw materials of 0.1mmol of 7-ethyl-10-hydroxycamptothecin, 2.0ml of dichloromethane and stearyl alcohol0.6mmol of isopropenyl ether, to which 0.005mmol of 1, 2-dichloroacetic acid was added with stirring. Reacting at room temperature, detecting by a dot plate, adding 300 mu l of triethylamine to the reaction solution after the reaction is completed, stopping the reaction, directly carrying out spin-drying, and carrying out silica gel column chromatography separation to obtain white solid SA-K-SN-38 with the yield of 76%.1H NMR (400MHz, chloroform-d): δ 8.14(d, J ═ 9.2Hz,1H),7.86(d, J ═ 2.4Hz,1H),7.68(s,1H),7.57(dd, J ═ 9.2,2.4Hz,1H),5.73(d, J ═ 16.2Hz,1H), 5.36-5.26 (m,1H),5.24(s,2H),3.66(dt, J ═ 19.9,6.8Hz,4H),3.13(q, J ═ 7.7Hz,2H), 1.98-1.82 (m,2H), 1.71-1.49 (m,10H), 1.45-1.15 (m,58H),0.87(t, J ═ 6.6Hz,3H).
Example 49: synthesis of stearyl alcohol-rapamycin acetonide conjugate (SA-K-Rap)
A15 ml Schlenk tube was taken, and 0.1mmol of rapamycin, 2.0ml of methylene chloride and 0.6mmol of stearyl isopropenyl ether as a raw material were added thereto, and 0.005mmol of 1, 2-dichloroacetic acid was added thereto with stirring. Reacting at room temperature, detecting by a dot plate, adding 300 mu l of triethylamine to terminate the reaction after the reaction is completed, directly carrying out spin-drying, and carrying out silica gel column chromatography separation to obtain white solid SA-K-Rap (mixture) with the yield of 46%.1H NMR (400MHz, chloroform-d): δ 6.36(qd, J ═ 14.9,10.1Hz,2H), 6.26-6.06 (m,2H),5.94(dd, J ═ 30.5,10.6Hz,1H), 5.62-5.38 (m,2H),5.29(d, J ═ 5.8Hz,1H), 5.21-5.08 (m,1H), 4.35-4.14 (m,2H), 3.93-3.79 (m,2H), 3.75-3.65 (m,2H), 3.54-3.45 (m,4H),3.42(s,3H),3.39(d, J ═ 3.9Hz,2H),3.34(s,3H),3.15(s,3H), 2.97-2.82 (m,2H),2.73(dd, 3.73, J ═ 3.9Hz,2H), 6.7, 6.15 (m,6H), 1.9H, 6.18H), 7, 6.15 (m,1H), 6.9H, 1H, 6H, 1H, 7 (1H), 3.9H, 6H, 7 (1H), 3.15 (1H), 3.9H, 6H, 1H, 6H), 3.9H, 1H, 6H, 1H, 6H, 1H), j ═ 12.5,6.8Hz,11H).
Example 50: synthesis of stearyl alcohol-fulvestrant acetonide conjugate (SA-K-FUL)
A15 ml Schlenk tube was taken, and 0.1mmol of fulvestrant protected with TBS, 2.0ml of methylene chloride and 0.6mmol of stearyl isopropenyl ether were added thereto, and 0.005mmol of 1, 2-dichloroacetic acid was added thereto with stirring. Reacting at room temperature, detecting by using a dot plate, adding 300 mu l of triethylamine after the reaction is completed, stopping, directly spin-drying, then adding 3ml of tetrahydrofuran, adding 1.0mmol of tetra-n-butylammonium fluoride, after the reaction is completed, adding 10ml of water, extracting by using ethyl acetate, collecting an organic phase, washing by using saturated salt water, using anhydrous sodium sulfate, filtering, concentrating, and separating by using silica gel column chromatography to obtain white solid SA-K-FUL with the yield of two steps of 61%.1H NMR (400MHz, chloroform-d): δ 7.15(d, J ═ 8.6Hz,1H),6.91(dd, J ═ 8.5,2.6Hz,1H),6.79(d, J ═ 2.5Hz,1H),3.74(t, J ═ 8.5Hz,1H),3.62(t, J ═ 6.9Hz,2H),2.87(dd, J ═ 16.8,5.4Hz,1H), 2.78-2.61 (m,5H), 2.37-2.23 (m,4H), 2.21-2.11 (m,3H),1.91(dt, J ═ 12.5,3.1Hz,1H),1.76(m,4H),1.61(m,5H),1.48(d, J ═ 2.9, 9H),1.26(s,47, 0.47H), t, 6.7H, 3H, 7H).
Example 51: synthesis of stearyl alcohol-abiraterone acetonide conjugate (SA-K-ABI)
Taking a 15ml Schlenk tube, adding 0.1mmol of abiraterone, 2.0ml of dichloromethane and 0.6mmol of n-tetradecyloxy isopropenyl ether which are raw materials into the Schlenk tube, adding 0.015mmol of 1, 2-dichloroacetic acid into the Schlenk tube under stirring, reacting at room temperature, adding 300 mu l of triethylamine into the Schlenk tube after the point plate detection reaction is completed, stopping direct spin-drying, and performing silica gel column chromatography separation to obtain a colorless oily product SA-K-ABI with the yield of 83%.1H NMR (400MHz, chloroform-d): δ 8.60(s,1H),8.43(d, J ═ 4.8Hz,1H),7.62(dt, J ═ 8.0,2.0Hz,1H),7.19(dd, J ═ 7.9,4.8Hz,1H),5.97(t, J ═ 2.7Hz,1H),5.33(t, J ═ 5.0Hz,1H), 3.65-3.55 (m,1H),3.43(t, J ═ 7.1Hz,2H), 2.36-2.15 (m,3H),2.04(ddd, J ═ 16.1,8.4,4.1Hz,3H), 1.88-1.40 (m,13H), 1.39-1.15 (m,28H), 1.14-0.97 (m,12H), t, 6.85H (t, 6H).
Example 52: synthesis of polyethylene glycol monomethyl ether-simvastatin acetonide conjugate (mPEG1000-K-SIM)
Simvastatin (0.1mmol) and mPEG1000 isopropenyloxy ether (0.6mmol) were placed in a Schlenk flask, dissolved by adding 2mL of tetrahydrofuran, followed by dichloroacetic acid (0.2eq) and reacted at 25 ℃. The reaction was followed by TLC, and after completion of the reaction, 100. mu.L of triethylamine was added to quench the reaction. After the solvent was spin-dried, the column was purified to obtain a white solid with a yield of 68%.1H NMR (400MHz, chloroform-d): δ 5.99(d, J ═ 9.7Hz,1H),5.78(m,1H),5.51(s,1H),5.37(d, J ═ 3.1Hz,1H), 4.67-4.56 (m,1H), δ 5.82-5.75 (m,1H), 3.85-3.79 (m,1H), 3.69-3.63 (m,90H),3.55(d, J ═ 2.0Hz,4H),3.38(s,3H),2.60(d, J ═ 25.7Hz,1H), 2.53-2.32 (m,3H), 2.29-2.19 (m,1H), 2.05-1.84 (m,6H), 1.73-1.65 (m,2H), 1.59-1.50 (m,3H),1.35 (m,6H), 1.15-6H), 1.9-6H (m, 1H).
Referring to the procedure of example 52, a acetonide prodrug thereof was prepared using lovastatin as a starting material.
TABLE 1 hydrolysis half-life and half inhibitory concentration of 2' -Taxol acetonide prodrug on MDA-MB-231 cells
TABLE 2 hydrolysis half-life and semi-inhibitory concentration of 2' -Taxol ketal prodrug on MDA-MB-231 cells
TABLE 3.7 hydrolysis half-life of paclitaxel acetonide prodrug and half inhibitory concentration on MDA-MB-231 cells
R-OH | t1/2(pH 5.0,min) | IC50(nM) |
Methanol | 31 | 18 |
|
3 | 13 |
Oleyl alcohol | 11 | 800 |
2- |
4 | 356 |
Polyethylene glycol monomethyl ether (molecular weight 164) | 53 | 32 |
Polyethylene glycol monomethyl ether (molecular weight 2000) | 297 | 32 |
TABLE 4 dexamethasone acetonide prodrug hydrolysis half-life and solubility in dichloromethane
R-OH | t1/2(pH 5.0,h) | Solubility (mM) |
Stearyl alcohol | 1.1 | 178 |
Oleyl alcohol | 1.2 | 229 |
2-octanol | 0.7 | 53 |
2-hexadecanol | 0.6 | 148 |
2-nonadecanol | 0.6 | 185 |
Menthol | 0.3 | 85 |
Polyethylene glycol monomethyl ether (molecular weight 1000) | 0.3 | 112 |
The inventors found that, similarly to the test results of the above-mentioned compounds, the solubility of the prodrug prepared via the above-mentioned examples can be significantly favorably improved relative to each starting drug, and the pharmacological activity thereof is also significantly superior to that of the commercially available starting drug, thereby making an unexpected significant improvement in improvement of the therapeutic effect and the kind of formulation.
Illustrative embodiments of the invention are described herein. It should be understood, however, that the scope of the present invention is not limited to the above-described embodiments. Any modification, equivalent replacement, improvement and the like made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.
Claims (10)
1. A compound represented by the following formula (I), a racemate, a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof:
wherein D is selected from the group consisting of a drug compound having at least one hydroxyl group, from which a hydrogen atom on one hydroxyl group has been removed;
R1selected from unsubstituted or optionally substituted by one, two or more RaSubstituted of the following groups: c1-40Alkyl radical, C3-20Cycloalkyl, 3-20 membered heterocyclyl, C6-20Aryl, 5-20 membered heteroaryl;
R2selected from or unsubstituted or optionally substituted by one, two or more RbSubstituted radicals-O-R4;
R3Selected from unsubstituted or optionally substituted by one, two or more RcSubstituted C1-40An alkyl group;
R4selected from substituents other than hydrogen;
each RaIndependently selected from halogen (such as F, Cl, Br, I), OH, SH, CN, N3Or unsubstituted or optionally substituted by one or more RbSubstituted of the following groups: c1-40Alkyl radical, C1-40Alkoxy radical, C2-40Alkenyl radical, C2-40Alkynyl, C3-20Cycloalkyl radical, C3-20Cycloalkyloxy, 3-20 membered heterocyclyl, 3-20 membered heterocyclyloxy, C6-20Aryl radical, C6-20Aryloxy, 5-20 membered heteroaryl, 5-20 membered heteroaryloxy, NRdRe、-CONRdRe、-C(O)YRf、-Y(O)CRf、-YP(O)(OM1)(OM2)、-YS(O)2OM3;
Each RbIndependently selected from F, Cl, Br, I, OH, SH, CN, N3Or unsubstituted or optionally substituted by one or more RcSubstituted of the following groups: c1-40Alkyl radical, C1-40Alkoxy radical, C2-40Alkenyl radical, C2-40Alkynyl, C3-20Cycloalkyl radical, C3-20Cycloalkyloxy, 3-20 membered heterocyclyl, 3-20 membered heterocyclyloxy, C6-20Aryl radical, C6-20Aryloxy, 5-20 membered heteroaryl, 5-20 membered heteroaryloxyGroup NRdRe、-CONRdRe、-C(O)YRf、-Y(O)CRf、-YP(O)(OM1)(OM2)、-YS(O)2OM3;
Each RcIndependently selected from F, Cl, Br, I, OH, SH, CN, N3Or unsubstituted or optionally substituted by one or more RaSubstituted of the following groups: c1-40Alkyl radical, C1-40Alkoxy radical, C2-40Alkenyl radical, C2-40Alkynyl, C3-20Cycloalkyl, 3-20 membered heterocyclyl, C6-20Aryl, 5-20 membered heteroaryl, NRdRe、-CONRdRe、-C(O)YRf、-Y(O)CRf、-YP(O)(OM1)(OM2)、-YS(O)2OM3;
Each RdAnd ReIndependently of one another, selected from H, or unsubstituted or optionally substituted by one or more RmSubstituted of the following groups: c1-40Alkyl radical, C2-40Alkenyl radical, C2-40Alkynyl, C3-20Cycloalkyl, 3-20 membered heterocyclyl, C6-20Aryl, 5-20 membered heteroaryl, -CONRfRg、-C(O)YRf、-Y(O)CRf、-YP(O)(OM1)(OM2)、-YS(O)2OM3;
Each RfAnd RgIndependently of one another, selected from H, or unsubstituted or optionally substituted by one or more RmSubstituted of the following groups: c1-40Alkyl radical, C2-40Alkenyl radical, C2-40Alkynyl, C3-20Cycloalkyl, COOH, 3-20 membered heterocyclyl, C6-20Aryl, 5-20 membered heteroaryl;
each RmIndependently selected from H, F, Cl, Br, I, OH, SH, CN, N3Or unsubstituted or optionally substituted by one or more RaSubstituted of the following groups: c1-40Alkyl radical, C1-40Alkoxy radical, C2-40Alkenyl radical, C2-40Alkynyl, C3-20Cycloalkyl, 3-20 membered heterocyclyl, C6-20Aryl, 5-20 membered heteroaryl, NRdRe、-CONRdRe、-C(O)YRf、Y(O)CRf、-YP(O)(OM1)(OM2)、-YS(O)2OM3;
Each Y is independently selected from the group consisting of a bond, -O-, -S-, or unsubstituted or optionally substituted with one or more Rasubstituted-NH-, C1-40Alkyl radical, C1-40Alkoxy radical, C3-20Cycloalkyl, 3-20 membered heterocyclyl, C6-20Aryl, 5-20 membered heteroaryl, - (CH)2CH2O)mWherein m is an integer of 0 or more, for example, an integer of 0 to 10;
M1、M2、M3independently of one another, selected from H, or unsubstituted or optionally substituted by one or more RaSubstituted C1-40An alkyl group;
when the pharmaceutical compound containing at least one hydroxyl group comprises two or more hydroxyl groups, at least one other hydroxyl group in the group D may be further removed from a hydrogen atom and reacted with-CR1R2R3A group shown is bonded, wherein R1、R2、R3Which may be the same or different at each occurrence, independently of one another, have the definitions described above.
2. The compound, its racemate, stereoisomer, tautomer or pharmaceutically acceptable salt thereof according to claim 1, wherein D is selected from the group consisting of pharmaceutical compounds containing at least one hydroxyl group, from which a hydrogen atom on one of the hydroxyl groups is removed, and which may be selected from the group consisting of, but not limited to:
taxanes (e.g., paclitaxel, docetaxel, cabazitaxel);
glucocorticoids (e.g., hydrocortisone, dexamethasone, prednisone, testosterone, estradiol, ethinyl estradiol, lynestrenone);
prostaglandin analogs (e.g., tafluprost, latanoprost, travoprost, bimatoprost, unoprostone isopropyl ester);
paliperidone;
artemisinin analogs (e.g., dihydroartemisinin);
nucleoside analogs (gemcitabine, trifluridine, idoxuridine, floxuridine, capecitabine, zalcitabine, cytarabine);
antiviral drugs (ganciclovir, acyclovir, emtricitabine, zidovudine, lamivudine, tenofovir, entecavir);
antibiotics (doxorubicin);
naltrexone;
rotigotine;
rapamycin, tacrolimus;
treprostinil;
amshufaxin;
etoposide; halofuginone;
combretastatin;
SN-38;
rapamycin;
fulvestrant;
abiraterone;
statins (simvastatin and lovastatin);
analgesic drugs (buprenorphine, oxymorphone, nalbuphine, levorphanol, hydromorphone, butorphanol); IDO inhibitor NLG 919; and
terpenoids are used as medicaments.
3. A compound, racemate, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof according to claim 1 or 2, wherein:
R1can be selected from unsubstituted or optionally substituted by one, two or more RaSubstituted of the following groups: c1-6Alkyl radical, C3-6Cycloalkyl, 3-6 membered heterocyclyl, C6-10Aryl, 5-6 membered heteroaryl;
preferably, R3Selected from unsubstituted or optionally substituted by one, two or more RcSubstituted C1-6An alkyl group;
preferably, R4Is selected from C1-40Alkyl radical, C2-40Alkenyl radical, C3-20Cycloalkyl radical, C3-20Cycloalkenyl group, 3-20-membered heterocyclic group, C6-20Aryl, 5-20 membered heteroaryl, -C1-40alkyl-OC (O) -PEG, -C1-40alkyl-OC (O) -PEG-C1-40Alkyl, -C1-40alkyl-OC (O) -C1-40alkyl-C (O) -PDLLA-PEG, -C1-40alkyl-OC (O) -C1-40alkyl-C (O) -PDLLA-PEG-C1-40Alkyl, -C1-40alkyl-OC (O) -C1-40alkyl-C (O) - (O-C)1-40alkyl-CO)p-(O-C1-40Alkyl radical)q-C1-40Alkyl, -C1-40alkyl-OC (O) -C1-40alkyl-C (O) - (O-C)1-40alkyl-CO)p-(O-C1-40Alkyl radical)q-H、-C1-40alkyl-OCO2-(C1-40alkyl-O)r-C1-40Alkyl, -C1-40alkyl-OCO2-(C1-40alkyl-O)r-H、-C3-20cycloalkyl-OC (O) -C1-40Alkyl- [ O-C1-40alkyl-C (O)]p-(O-C1-40Alkyl radical)q-O-C1-40Alkyl, -C3-20cycloalkyl-OC (O) -C1-40Alkyl- [ O-C1-40alkyl-C (O)]p-(O-C1-40Alkyl radical)q-OH、-C1-40alkyl-OC (O) -C1-40Alkyl- [ O-C1-40alkyl-C (O)]p-(O-C1-40Alkyl radical)q-O-C1-40Alkyl, -C1-40alkyl-OC (O) -C1-40Alkyl- [ O-C1-40alkyl-C (O)]p-(O-C1-40Alkyl radical)q-OH、-C3-20cycloalkyl-O- (C)1-40alkyl-O)r-C1-40Alkyl, -C3-20cycloalkyl-O- (C)1-40alkyl-O)r-H、-(C1-40alkyl-O)r-C1-40Alkyl, - (C)1-40alkyl-O)r-H、-C3-20cycloalkyl-C1-40Alkyl, -hydroxy or C1-40An alkyl hydroxy-substituted 3-20 membered heterocyclic group; wherein the subscripts of the repeating units, such as p, q, r, are the same or different from each other and are independently selected from a number of from 1 to 500, such as a number of from 1 to 200, for example an integer of from 1 to 200;
or, -O-R4Selected from ethylene glycol and ethylene glycolGlycol monoalkyl ethers (e.g. polyethylene glycol mono C)1-40Alkyl ethers), polyethylene glycol (PEG) or polyethylene glycol monoalkyl ethers (e.g. polyethylene glycol mono C)1-40Alkyl ether) to remove a hydrogen atom from a hydroxyl group at the end of polyethylene glycol;
the R isa、Rb、RcIdentical or different, independently of one another, from the group consisting of F, Cl, Br, I, OH, SH, CN, N3、=O、C1-20Alkyl radical, C2-20Alkenyl radical, C3-20A cycloalkyl group;
preferably, the molecular weight of the PEG and the molecular weight of the PDLLA are the same or different, and are independently selected from 100-5000.
4. A compound according to any one of claims 1 to 3, racemates, stereoisomers, tautomers or pharmaceutically acceptable salts thereof, wherein:
Preferably, said R is2Is selected from a substituent obtained by removing a hydrogen atom on one hydroxyl group of polyethylene glycol, or a substituent obtained by removing a hydrogen atom on one hydroxyl group of polyethylene glycol monoalkyl ether, or is selected from the following groups:
6. a process for the preparation of a compound according to any one of claims 1 to 5, racemates, stereoisomers, tautomers or pharmaceutically acceptable salts thereof, comprising reacting a compound of formula D-H with a compound of formula (I-1) to give a compound of formula (I):
wherein, D, R1、R2、R3Independently of each other, have the definitions in any one of claims 1 to 5;
Rhh selected from CH and D-H capable of being linked thereto combines to form R3Or R ishIs selected from R3Removal of the group CH2The resulting radical.
8. A pharmaceutical composition comprising a therapeutically effective amount of a compound of any one of claims 1-5, racemates, stereoisomers, tautomers or pharmaceutically acceptable salts thereof.
9. The use of a compound according to any one of claims 1 to 5, racemates, stereoisomers, tautomers or pharmaceutically acceptable salts thereof in the prevention or treatment of disease or condition, said disease being a disease or condition which can be treated by said pharmaceutical compound containing at least one hydroxyl group, such as those that can reduce or alleviate signs or symptoms of a disease or condition upon administration of a taxane, glucocorticoid, prostaglandin analog, paliperidone, artemisinin analog, nucleoside analog, antibiotic, antiviral drug, naltrexone, rotigotine, rapamycin, tacrolimus, treprostinil, amsufamine, etoposide, halofugine, combretastatin, SN-38, rapamycin, fulvestrant, abiraterone, statin, analgesic, IDO inhibitor NLG919, or terpenoid.
10. The compound shown in the formula (I), racemate, stereoisomer, tautomer or pharmaceutically acceptable salt thereof, or the application of the pharmaceutical composition in improving the physical property, the chemical property or the pharmaceutical property of the pharmaceutical compound containing at least one hydroxyl.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2019107138640 | 2019-08-02 | ||
CN201910713864 | 2019-08-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN112300099A true CN112300099A (en) | 2021-02-02 |
Family
ID=74336337
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010175551.7A Pending CN112300099A (en) | 2019-08-02 | 2020-03-13 | Ketal derivatives of drugs, preparation method thereof, pharmaceutical compositions and uses |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112300099A (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115260190A (en) * | 2022-08-30 | 2022-11-01 | 南开大学 | Prapidone prodrug, preparation method and application thereof |
CN116354968A (en) * | 2023-03-14 | 2023-06-30 | 南开大学 | Navomod prodrugs and nanoparticles that bind to endogenous lipoproteins |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101569748A (en) * | 2008-04-30 | 2009-11-04 | 宁波大学 | Water-soluble taxol prodrug, preparation method and chemical modifier thereof |
CN103763928A (en) * | 2011-06-06 | 2014-04-30 | 阿伯疗法责任有限公司 | Acid-labile lipophilic prodrugs of cancer chemotherapeutic agents |
-
2020
- 2020-03-13 CN CN202010175551.7A patent/CN112300099A/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101569748A (en) * | 2008-04-30 | 2009-11-04 | 宁波大学 | Water-soluble taxol prodrug, preparation method and chemical modifier thereof |
CN103763928A (en) * | 2011-06-06 | 2014-04-30 | 阿伯疗法责任有限公司 | Acid-labile lipophilic prodrugs of cancer chemotherapeutic agents |
Non-Patent Citations (2)
Title |
---|
BEOM-YOUNG RYU1 ET AL: "Synthesis and anti-cancer efficacy of rapid hydrolysed water-soluble paclitaxel pro-drugs", 《J. BIOMATER. SCI. POLYMER EDN》, vol. 19, no. 3, 31 December 2008 (2008-12-31), pages 311 - 324 * |
元英进等: "《抗癌新药紫杉醇和多烯紫杉醇》", 化学工业出版社, pages: 178 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115260190A (en) * | 2022-08-30 | 2022-11-01 | 南开大学 | Prapidone prodrug, preparation method and application thereof |
CN116354968A (en) * | 2023-03-14 | 2023-06-30 | 南开大学 | Navomod prodrugs and nanoparticles that bind to endogenous lipoproteins |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN112351976B (en) | Taxane-lipid-polysaccharide double-type coupling body, preparation method and application thereof | |
US20100010059A1 (en) | Anticancer oral formulation | |
WO2014145303A1 (en) | Intravenous emulsions of triptolide as immunomodulators and anticancer agents i | |
CN106946975B (en) | Triptolide derivative and preparation method and preparation thereof | |
CN112300099A (en) | Ketal derivatives of drugs, preparation method thereof, pharmaceutical compositions and uses | |
KR20190077476A (en) | Uses of phosglycerin macrocyclic analogs as anticancer compounds | |
CN106432141B (en) | Preparation method and application of cabazitaxel prodrug | |
KR20120094546A (en) | Polymer micelles containing sn-38 for the treatment of cancer | |
CN107001302B (en) | Water-soluble taxane derivatives and application thereof | |
CN111372939A (en) | Preparation of trans- [ tetrachlorobis (1H-indazole) ruthenium (III) ] and compositions thereof | |
JP2007515425A (en) | Pharmaceutical composition | |
EP4028447B1 (en) | Polymer and composition from renewable source | |
CN111793147B (en) | Modified chitosan, double-response nano-carrier drug, and preparation method and application thereof | |
CN106554330A (en) | Water-soluble docetaxel anti-cancer drug compounds and its preparation method and application | |
CN113620969A (en) | Cyclohexane dicarboxylic acid derivative with bridged ring, and pharmaceutical composition and application thereof | |
WO2007134533A1 (en) | 20(R)-GINSENOSIDE Rg3 MEDICINAL SOLUBLE INTERMEDIATE AND PROCESS THEREOF | |
JP2003531130A (en) | Water-soluble prodrug compound containing the residue of paclitaxel or a derivative thereof, method for producing the same, and pharmaceutical composition containing the same | |
CN116133693A (en) | Drug-loaded macromolecule and preparation method thereof | |
US11833128B2 (en) | Ketone carbonyl-containing hydrophobic antitumor drug and conjugate thereof as well as nano preparation containing conjugate, preparation method therefor, and application thereof | |
JP7495352B2 (en) | Stereocomplexation of oligolactate conjugates in micelles for improved physical stability and enhanced antitumor efficacy | |
KR20220119085A (en) | Formulated and/or co-formulated liposome compositions containing toll-like receptor (“TLR”) agonist prodrugs useful for the treatment of cancer and methods thereof and methods thereof | |
CN112656950A (en) | Camptothecin-polycaprolactone coupled prodrug, preparation method and application thereof | |
CN105777769A (en) | 7-ethyl-10-hydroxycamptothecin derivatives, and preparation and application thereof | |
CN115089720B (en) | Tumor treatment medicine composition | |
JP2019513151A (en) | Camptothecin derivatives and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210202 |